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ABSTRACT 
Bovine herpesvirus 1 (BHV-1) is a member of the Alphaherpesvirinae subfamily and is 
the prototype ruminant herpesvirus. BHV-1 causes a number of complications in cattle including 
upper respiratory tract disorders, conjunctivitis, genital disorders, abortions, and immune 
suppression. Like all herpesviruses, reactivation from latency can occur throughout the animal‟s 
life. Of particular economic importance is the bovine respiratory disease complex (BRDC) or 
„shipping fever‟, in which BHV-1 plays a major role. BRDC is an enormous economic concern 
as it costs the US cattle industry approximately one billion dollars annually.  
In order to generate improved gene-deleted vaccines against BHV-1, there is a need to 
understand the contributions of viral gene products during infection. US3 is a serine/threonine 
kinase present in BHV-1 and is thought to play major roles during viral infection.  As in other 
herpesviruses, US3 in BHV-1 is expected to phosphorylate several cellular and/or viral proteins. 
We recently presented evidence that BHV-1 US3 phosphorylates both VP8 and VP22; however, 
further functional characteristics of BHV-1 US3 during viral infection have not been elucidated.  
The hypothesis of this project is that the deletion of the US3 gene leads to reduced BHV-
1 fitness. To explore this hypothesis, we generated a US3-deleted (ΔUS3) and subsequent US3-
rescued (US3R) BHV-1 virus. Using these viral mutants, we characterized the growth properties 
of the viruses, evaluated the effect of the US3 deletion on major structural BHV-1 proteins, 
characterized the protein composition of the mature virions, and, identified viral processes that 
were impaired in the deletion mutant.  
Initially, the ∆US3 virus was generated through a 3-step PCR strategy which replaced the 
gene of interest with an antibiotic resistance cassette. Following this, the US3 gene was rescued 
via a two-step en passant mutagenesis strategy which has been previously used to generate 
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insertions, deletions, and substitutions in herpesvirus-containing bacterial artificial chromosome 
(BAC) DNA. 
In vitro characterization of ∆US3 BHV-1 has demonstrated that US3 deletion affects 
BHV-1 growth characteristics, expression kinetics of major structural proteins, mature virion 
composition, cell to cell spread, and the subcellular localization of key viral proteins during 
infection. Growth kinetics of ∆US3 BHV-1 were impaired compared to wild-type (WT) BHV-1, 
especially at late times post-infection. Plaque sizes formed by ∆US3 BHV-1 were significantly 
smaller than those formed by either WT or US3R BHV-1, demonstrating that US3 is important 
for cell to cell spread. The expression kinetics of major structural and regulatory BHV-1 proteins 
were different between cells infected with ∆US3 or WT BHV-1, and incorporation of these 
proteins into the mature viruses differed, demonstrating that US3 is instrumental in ensuring 
proper protein expression and mature virus composition in vitro.  
Of particular importance, glycoprotein B (gB), was shown to be expressed in higher 
quantities earlier during infection in the absence of US3, and that this protein was incorporated in 
significantly higher amounts in mature virions which lacked US3. Qualitative analysis of ∆US3 
BHV-1 infected monolayers suggested the abolishment of cell to cell projections characteristic of 
WT BHV-1 infection. Finally, the disruption of gB in ∆US3 BHV-1 infected cells was confirmed 
by confocal microscopy and fluorescence-activated cell sorting (FACS) analysis. Through 
confocal microscopy, evidence was provided that infection with ∆US3 BHV-1 possibly results in 
earlier expression of gB on the surface of cells and less intracellular accumulation of this protein 
during late stages of infection. The observed effect on the localization of intracellular gB in 
∆US3 BHV-1 infected cells was quantified by flow cytometry. ∆US3 BHV-1 infected cells had 
approximately 25% higher gB expression on the surface of cells and a corresponding 25% 
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decrease in intracellular gB.  Although these differences have not yet been demonstrated to be 
statistically significant and not confirmed through infection with US3R BHV-1, this suggests 
that US3 may influence the synthesis and cellular trafficking of gB in vitro. 
v 
 
ACKNOWLEDGEMENTS 
First off, I would like to thank my graduate supervisor, Dr. Sylvia van Drunen Littel – 
van den Hurk for her supervision. I have appreciated the opportunity to study in such a diverse 
field and have valued her guidance, expertise, and resourcefulness throughout the course of my 
research. Additionally, I would like to thank my advisory committee, Dr. Joyce Wilson and Dr. 
Suresh Tikoo for their guidance and encouragement throughout this project. Funding for this 
project was provided by the Canadian Institutes of Health Research and Natural Sciences and 
Engineering Research Council, as well as from a scholarship through the Department of 
Vaccinology and Immunotherapeutics.   
I would like to extend many thanks to all of the friends and colleagues I have made while 
studying at VIDO. Not only is there a great wealth of knowledge in the building, it houses some 
of the greatest people that I‟ve ever had the pleasure of working with. Specifically, I would like 
to thank Dr. Robert Brownlie for his molecular expertise and assistance with my project. I would 
also like to thank Marlene Snider for her technical expertise and support during my confocal 
studies. Not only have these people made me into a more skilled researcher, they have both 
become great friends of mine. Finally, I would like to thank Natasa Arsic and Ravendra Garg for 
their assistance with my FACS analyses and for the time they have devoted to my project.  
There are too many past and present lab mates to thank, but specifically I would like to 
extend my gratitude to Dr. Vladislav Lobanov, Dr. Karl Robinson, and Luana Dummer for their 
help with this project. I have enjoyed the time I have spent with all of the people from A321, and 
will miss all the laughs, camaraderie, and stories that we shared on a daily basis.  
Lastly, I would like to thank my greatest support during this project: My family. Thanks 
to my parents, Robert and Janet Lee, for their unwavering encouragement and belief in me and 
vi 
 
my dreams. You have given me the confidence and strength to believe that anything is possible if 
I put my mind to it. Thanks to my in-laws for their love and support. Lastly, I owe the greatest 
thanks to my wonderful husband, Andrew, who has been there every step of the way through this 
journey called graduate school.  
vii 
 
DEDICATION 
This thesis is dedicated to my family. 
viii 
 
 
Tables of Contents 
PERMISSION TO USE ...................................................................................................................................... i 
ABSTRACT ...................................................................................................................................................... ii 
ACKNOWLEDGEMENTS ................................................................................................................................. v 
DEDICATION ................................................................................................................................................ vii 
LIST OF TABLES .............................................................................................................................................. x 
LIST OF FIGURES ........................................................................................................................................... xi 
LIST OF ABBREVIATIONS ............................................................................................................................. xii 
1.0 Literature Review .................................................................................................................................... 1 
1.1 Introduction to BHV-1 ............................................................................................................................. 1 
1.1.1 Nomenclature and Classification ..................................................................................................... 1 
1.1.2 Disease and Importance .................................................................................................................. 1 
1.1.2.1 Clinical Manifestations .............................................................................................................. 1 
1.1.3 Vaccines ....................................................................................................................................... 4 
1.2 BHV-1 genome and virus composition ................................................................................................ 6 
1.3 Alphaherpesvirus replication cycle ................................................................................................... 10 
1.4 Latency .............................................................................................................................................. 14 
1.5 Alphaherpesvirus US3 serine/threonine kinase ............................................................................... 15 
1.5.1 Function of US3 in HSV-1 and PRV ............................................................................................. 15 
1.5.2 Putative functions of US3 in BHV-1 ............................................................................................ 21 
2.0 HYPOTHESIS AND OBJECTIVES .............................................................................................................. 25 
3.0 MATERIALS AND METHODS .................................................................................................................. 27 
3.1 Cloning .............................................................................................................................................. 27 
3.1.1 Construction of ΔUS3 pBHV-1 BAC ............................................................................................ 27 
3.1.2 Construction of US3R pBHV-1 BAC ............................................................................................ 29 
3.1.3 Verifying mutant virus integrity ................................................................................................. 37 
3.2 Propagation and titration of viruses in cell culture .......................................................................... 38 
3.3 Single-step growth curves ................................................................................................................. 39 
3.4 Expression kinetics assay .................................................................................................................. 39 
3.4.1 Preparation of BHV-1 infected cell lysates ................................................................................ 39 
ix 
 
3.4.2 SDS-PAGE ................................................................................................................................... 39 
3.4.3 Western Blot .............................................................................................................................. 40 
3.5 Purification of BHV-1 viruses ............................................................................................................ 40 
3.5.1 Normalization of the purified virus ............................................................................................ 41 
3.6 Plaque-size quantification ................................................................................................................. 42 
3.7 Light microscopy of BHV-1 infected MDBK cells ............................................................................... 42 
3.8 Confocal microscopy of BHV-1 infected MDBK cells ........................................................................ 42 
3.9 Fluorescence-Activated Cell Sorting (FACS) ...................................................................................... 43 
4.0 RESULTS................................................................................................................................................. 44 
4.1 Construction and verification of ΔUS3 and US3R pBHV-1 ................................................................ 44 
4.2 Single-step growth curves of WT, ΔUS3 and US3R BHV-1 ................................................................ 46 
4.3 Effect of US3 deletion on the expression kinetics of major BHV-1 proteins .................................... 50 
4.4 Effect of US3 on the protein composition of the mature virion ....................................................... 51 
4.5 The role of US3 in cell to cell spread ................................................................................................. 55 
4.6 Effect of US3 on infected monolayers during BHV-1 infection in vitro ............................................ 55 
4.7 Effect of US3 on the subcellular localization of tubulin, VP22, VP8, and gB .................................... 57 
4.8 Effect of US3 on the surface expression of gB in vitro ...................................................................... 67 
5.0 DISCUSSION AND CONCLUSIONS .......................................................................................................... 76 
6.0 GENERAL CONCLUSIONS AND FUTURE DIRECTIONS ............................................................................ 89 
7.0 REFERENCES .......................................................................................................................................... 93 
 
 
x 
 
LIST OF TABLES 
 
Table 1.1: Major BHV-1 genes discussed or investigated in this study (91, 99, 125, 132) ........................... 8 
Table 1.2: Amino acid sequence similarities between various US3 orthologues ....................................... 17 
Table 3.1: Primers used for PCR .................................................................................................................. 34 
Table 3.2: PCR program used for amplification of oligonucleotides .......................................................... 35 
xi 
 
LIST OF FIGURES 
 
Figure 1.1: Schematic of the BHV-1 genome and the US2, US3, and US4 gene organization. ..................... 9 
Figure 1.2: Schematic of the alphaherpesvirus replication cycle. .............................................................. 11 
Figure 3.1: Generation of a ΔUS3 pBHV-1 mutant...................................................................................... 28 
Figure 3.2: ΔUS3 pBHV-1 rescue using the en passant mutagenesis strategy (134). ................................. 32 
Figure 3.3: Maps of the altered US3 region in WT, ΔUS3, and Rescue-zeo pBHV-1. .................................. 36 
Figure 4.1: HindIII-digestion of ΔUS3, WT and US3R BHV-1. ...................................................................... 47 
Figure 4.2: US3 expression profiles of WT, ΔUS3 and US3R BHV-1 infected cells. ..................................... 48 
Figure 4.3 a, b: Growth characteristics of WT, ΔUS3 and US3R BHV-1. ..................................................... 49 
Figure 4.4 a, b, c: Effect of BHV-1 US3 on viral protein expression during infection. ................................ 52 
Figure 4.5 a,b: Effect of US3 on the mature virion composition of BHV-1. ................................................ 54 
Figure 4.6: Effect of US3 on cell to cell spread in vitro. .............................................................................. 56 
Figure 4.7: Deletion of US3 influences cell morphology in BHV-1 infected MDBK cells. ............................ 58 
Figure 4.8: US3-dependent changes in cell morphology occur over the course of infection..................... 59 
Figure 4.9: US3 localizes to the nucleus during BHV-1 infection and is absent in ΔUS3-infected cells. ..... 61 
Figure 4.10: BHV-1 US3 may affect maintenance of cellular adhesions that are facilitated through 
cytoskeleton restructuring. ......................................................................................................................... 62 
Figure 4.11: The intracellular localization of BHV-1 VP22 is not dependent on US3. ................................ 64 
Figure 4.12: BHV-1 VP8 localizes to the nucleus of infected cells independent of US3. ............................ 65 
Figure 4.13 a,b:  Intracellular expression of gB in cells infected with WT and ΔUS3 BHV-1. ..................... 70 
Figure 4.14 a,b: Surface expression of gB in cells infected with WT and ΔUS3 BHV-1. .............................. 73 
Figure 4.15 a, b, c: Intracellular and surface expression of gB in WT and ΔUS3 BHV-1. ............................ 74 
xii 
 
LIST OF ABBREVIATIONS 
˚C  degree Celsius 
a.a.  amino acid 
AP  adaptor protein 
APS  ammonium persulfate 
ATP  adenosine triphosphate 
BAC  bacterial artificial chromosome 
BCIP  5-bromo-4-chloro-3-indolylphosphate 
BHV-1  bovine herpesvirus type 1 
BHV-5  bovine herpesvirus type 5 
bp  base pairs 
BRDC  bovine respiratory disease complex 
BRSV  bovine respiratory syncytial virus 
BVDV  bovine viral diarrhea virus 
CD  cluster of differentiation 
Cdc42  cell division control protein 42 homolog 
CK2  cellular casein kinase 2 
cm  centimetres 
CMI  cell-mediated immunity 
CO2  carbon dioxide 
ddH20  double distilled water 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
E  early 
FACS  fluorescence-activated cell sorting 
FBS  fetal bovine serum 
FBT  Fetal Bovine Tracheal cells 
gB  glycoprotein B. All viral glycoproteins are designated with the prefix „g.‟ 
GFP  green fluorescent protein 
GTP  guanosine triphosphate 
HCL  hydrochloric acid 
HSV-1  herpes simplex virus type 1 
xiii 
 
HSV-2  herpes simplex virus type 2 
IBRD  infectious bovine rhinotracheitis disorder 
IE  immediate-early 
IFN-   interferon gamma 
Ig  immunoglobulin 
IR  internal repeat 
I-SceI  inducible homing endonuclease SceI 
kb  kilobase 
kD  kilodalton 
KV  killed vaccine 
kV  kilovolts 
L  late 
LAT  latency-associated transcript 
LT  linear transgene 
MAb  monoclonal antibody 
mAmps milliamps  
MDBK  Madin Darby Bovine Kidney cells 
MDV  Marek‟s Disease virus 
MFI  mean fluorescent intensity 
MHC  major histocompatibility complex 
ml  millilitre 
MLV  modified live vaccine 
mm  millimetre 
MOI  multiplicity of infection 
mRNA  messenger ribonucleic acid 
NBT  nitroblue tetrazolium 
ng  nanograms 
ORF  open reading frame 
PAb  polyclonal antibody 
PAK  serine/threonine protein kinase 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PFU  plaque-forming units 
xiv 
 
PMSF  phenylmethylsulfonyl fluoride 
PRV  pseudorabiesvirus 
Rac1  Ras-related C3 botulinum toxin substrate 1  
RCF  relative centrifugal force 
Rho   factor 
RPM  revolutions per minute 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TEMED N,N,N‟,N‟-tetramethylethylenediamine 
Thr-887 threonine residue 887 
TR  terminal repeat 
Tyr-889 tyrosine residue 889 
UL  unique long 
US  unique short 
US3R  US3-rescued  
v/v  volume per volume 
w/v  weight per volume 
WT  wild-type 
ΔUS3  US3-deleted  
μg  micrograms 
Ω  ohm 
F  microfarads 
l  microlitres 
1 
 
1.0 Literature Review 
1.1 Introduction to BHV-1 
1.1.1 Nomenclature and Classification 
BHV-1 is a member of the Varicellovirus genus and Alphaherpesvirinae subfamily and is 
the prototype ruminant herpesvirus (125). It is the causative agent of infectious bovine 
rhinotracheitis disorder (IBRD) and shipping fever, which cause a number of complications in 
cattle worldwide.  
BHV-1 is classified into subtypes 1.1, 1.2a, and 1.2b. Each of the subtypes has different 
DNA restriction endonuclease profiles (89), cause different clinical manifestations in their hosts 
(98), and has different geographical distributions (51). Subtype 1.1 is the most pathogenic and is 
typically isolated from cattle with BHV-1-induced respiratory disease, causing bovine 
rhinotracheitis and abortions. This subtype is most prevalent in North America, Europe, and 
South America. Subtype 1.2a (2a) is geographically restricted to Brazil and causes a broad range 
of symptoms, including genital and respiratory infections, and abortions (142).  Subtype 1.2b 
(2b) is found in Australia and Europe and is associated with milder clinical disease, causing 
respiratory and genital infections in cattle (51). Subtypes 1.1 and 1.2a are capable of causing 
abortion, where as subtype 1.2b is not (89).   
1.1.2 Disease and Importance 
1.1.2.1 Clinical Manifestations 
Clinical manifestations of BHV-1 were primarily restricted to genital disorders in the 
early 19
th
 century (98). In the early 1950's, however, a more severe form of the disease showed 
up in North American feedlots. This form of the disease affected the upper respiratory tract of 
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cattle, leading to IBRD (123). IBRD spread rapidly across North America and to Europe due to 
importation of dairy cattle from infected feedlots (98). 
Since its discovery, BHV-1 has been further characterized as a multifaceted disease 
affecting a wide range of tissues and causing symptoms in cattle ranging from upper respiratory 
tract disorders, conjunctivitis, genital disorders, abortions, to immune suppression in cattle (51, 
98). Primary infection with BHV-1 includes inoculation at a mucosal surface and a 1-6 day 
incubation period depending on the strain and mode of transmission (51, 133). After incubation, 
virus-loaded lesions appear in the infected areas and usually resolve within 4-5 days for 
respiratory infections, and about two weeks for genital infections. BHV-1 induced respiratory 
infections cause high fever, salivation, nasal and ocular discharge, anorexia, coughing, and 
numerous nasal lesions on the septal mucosa (51).  Although abortions often occur in parallel 
with acute respiratory infection, they can also occur through BHV-1 reactivation up to 100 days 
after acute infection.  Symptoms caused by genital infections with subtypes 2a and 2b often 
begin as an increased urination frequency followed by the appearance of lesions on the genitals 
of infected animals. Infections with BHV-1 tend to be complicated by secondary infections 
caused by a weakened immune system in the infected animal and usually require antibiotics 
(155).  
Although a multifactorial disease, BHV-1 is known to play a primary role in the 
development of full BRDC. In addition to BHV-1, stress and other viral pathogens, such as 
parainfluenza-3 virus, bovine respiratory syncytial virus (BRSV), and bovine viral diarrhoea 
virus (BVDV), contribute to the formation of BRDC through immune suppression which 
eventually leads to secondary infections caused by M. haemolytica and P. multocida (51, 155). 
BRDC is characterized by high fever, anorexia, coughing, excessive salivation, nasal discharge, 
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inflamed nares, pneumonia and dyspneae (51, 155). BHV-1 is thought to cause BRDC through 
immunosuppression of the host due to down regulation of the major histocompatibility complex 
(MHC) class I (40, 51, 101) and through apoptosis of infected CD4+ T cells early in infection 
(152).  
Similar to all primary alphaherpesvirus infections, BHV-1 gains access to the local 
sensory neurons and establishes latency in the ganglia (2, 3). Reactivation of BHV-1 from 
latency can occur throughout the animal‟s life and can cause serious respiratory disease, abortion 
of the fetus, and transmission of the virus to disease-free animals.   
1.1.2.2 Epidemiology 
 BHV-1 is widely distributed throughout the world. Australia, New Zealand, Canada, and 
the USA have variable but high seroprevalence rates (1). Despite control measures, BHV-1 is 
endemic in many European and South American countries (21). Complicating the problem 
further, BHV-1 and BHV-5 have been shown to co-infect cattle in countries such as Argentina 
and Brazil, where vaccination against BHV-1 is not mandatory and where BHV-5 infections are 
prevalent (15). 
 BHV-1 risk factors include sex (higher incidence in males), age, herd size, direct animal 
contact, and farm density (9, 129, 143, 147).  Since BHV-1 is latent in its host and can reactivate 
at any point, latently infected animals are the major source of transmission to uninfected herds. 
Therefore, since cattle populations in North America are large, transmission of the virus from 
latently infected cattle to uninfected herds is difficult to control. The virus is easily spread via 
mating, birth, transport, and through the introduction of infected heifers into dairy cattle herds 
(98). Transmission of the virus through a non-cattle ruminant reservoir is not likely to be a major 
source of BHV-1 transmission (132).  
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1.1.2.3 Cell Tropisms 
 BHV-1 has limited cell tropisms, infecting the epithelial cells of the upper respiratory 
tract, the genital tract, and the conjunctiva (98), and can infect CD4+ cells (152). Infection of the 
upper respiratory tract most commonly occurs through direct nose to nose contact, but can occur 
through aerosol droplets at short distances (81). Entry of the virus through the genitals usually 
occurs through mating or through artificial insemination by virus-infected semen (63). After 
replication in the epithelial mucosa, the virus gains access to the ganglia to establish latent 
infection in neurons (105). Systemic spread of the virus is possible when the mucosal barriers are 
compromised (82), and the resulting viremia is associated with abortion of the unborn fetus (18) 
and fatal systemic infection in calves (42).  
1.1.2.4 Economic Importance of BRDC 
BHV-1 is of particular economic importance due to the role that it plays in the 
development of BRDC or „shipping fever‟ (51). BRDC is an enormous economic concern as it 
costs the US cattle industry approximately 640 million annually due to weight loss, decreased 
milk production, abortions, and restrictions on international trade (11, 100). Since recovered 
cattle remain lifetime carriers of the virus, they are considered dangerous to disease-free herds 
since they can introduce the virus under immunosuppressive conditions (108, 142). 
1.1.3 Vaccines 
BHV-1 has been eradicated from a number of European countries including Denmark, 
Switzerland, Austria, Finland, Sweden, and Norway by culling of seropositive herds (102, 130). 
This method is acceptable in countries which harbour small cattle populations that can be 
controlled. A similar method, however, is unfeasible for countries with large cattle populations, 
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such as those present in North America. In these countries, vaccination remains the most feasible 
method of BHV-1 eradication, however, vaccination programs to date have been largely 
unsuccessful (1). 
There are two types of commercially available vaccines against BHV-1, namely modified 
live vaccines (MLV) and inactivated vaccines (51). Although considerable efforts have been 
made to generate vaccines against BHV-1, all have been shown to have problems with efficacy 
or safety (98). Currently, subunit vaccines, DNA vaccines, gene-deleted, and vector based 
vaccines are in pre-clinical development.  
Vaccines against BHV-1 are generally evaluated based on absence of clinical symptoms, 
low viral shedding upon challenge and high neutralizing antibody titer (51).  Recently, it was 
demonstrated that in addition to a high IFN-  response by T cells, increased expression of CD25 
is indicative of BHV-1 immunity (27).  
Early studies on BHV-1 vaccines were focused on generating MLV and killed vaccines 
(KV). MLV are able to replicate in cells, therefore inducing rapid and long-lasting humoral and 
cell-mediated immune (CMI) responses (150). Although quite efficient, MLV have problems 
with safety, including inducing immunosuppression in calves and abortion in pregnant cows due 
to reactivation from latency (100).  Furthermore, it has been noted that there have been a number 
of BRDC outbreaks in feedlot cattle which were previously immunized with MLV (139).  
Although a safe alternative to MLV, KV only elicit a humoral response and are incapable 
of inducing a CMI response. Other drawbacks to KV include  requiring more than one dose, the 
need for adjuvants, and the possibility of the antigenic structures becoming denatured during the 
inactivation process, which may affect immunogenicity (51).  
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Due to the problems associated with commercial MLV and KV, genetically engineered 
gene-deleted, subunit, and vectored BHV-1 vaccines are being investigated as potentially more 
efficient and safe for use in cattle. Furthermore, gene-deleted, subunit, and vectored vaccines 
have the added advantage of differentiating vaccinated from non-vaccinated animals. Various 
gene-deleted vaccines have been constructed, but most have had issues with reactivation from 
latency or virulence (50). A glycoprotein E (gE)-deleted vaccine, however, was shown to be 
extremely safe and has been successful in eradicating BHV-1 from several European countries. 
Although it has an excellent safety profile, this vaccine has been shown to be less efficacious 
than other glycoprotein-deleted vaccines (53).  Efforts are being made to identify 
immunosuppressive BHV-1 motifs that can be deleted along with gE to improve the vaccine 
efficacy (50). A glycoprotein D (gD) subunit vaccine has been demonstrated to be highly 
protective when formulated with adjuvants such as a mineral oil emulsion and a CpG 
oligodeoxynucleotide (46, 140). Vectored vaccines which express gD using either DNA or 
bovine adenovirus have been shown to be successful and may be useful in immunizing neonates 
due to resilience in the face of maternal antibodies (137, 156).  
BHV-1 is ideal as a vaccine vector due to its large size, which easily accommodates 
foreign genes, and its limited host range (6, 79). The virus been used successfully as a vaccine 
vector to immunize cattle against pathogens such as BVDV and BRSV (64, 120). To continue to 
improve BHV-1 subunit and marker vaccines, as well as increase the potential for BHV-1 to be 
an effective vaccine vector, more research is needed to understand the contributions of individual 
BHV-1 gene products to viral fitness and pathogenicity in the host.   
1.2 BHV-1 genome and virus composition 
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Like other Herpesviridae, BHV-1 is a large, pleomorphic virus that contains four 
morphologically distinct compartments (114). These compartments include the genome-
containing core inside the icosahedral capsid, surrounded by the proteinaceous tegument layer 
that links the capsid to the outer cell-derived envelope (85, 86).   
Together, the icosahedral capsid and the viral genome make up the viral nucleocapsid. 
The 136 kilobase (kb) BHV-1 genome contains linear double-stranded DNA encoding 
approximately 70 proteins, with 33 known structural proteins and 15 non-structural proteins (91, 
98, 125) (Table 1.1). In 2008, a random insertional mutagenesis study by Robinson et al. 
demonstrated that in cell culture, BHV-1 has 33 essential open reading frames (ORF) and 36 
non-essential ORF (113). The genome is extremely guanine and cytosine rich (72%) and many 
proteins are conserved within the Alphaherpesvirinae subfamily (146).  
Belonging to class D herpesvirus genomes, the BHV-1 genome contains a unique long 
(UL) and unique short (US) region with two inverted repeat sequences that flank the US region, 
called the internal repeat (IR) and the terminal repeat (TR) (127) (Figure 1.1).  During genome 
replication, the repeats result in packaging of equimolar amounts of two isomers in which the US 
region is in either orientation and the UL region is fixed (114). These isomeric forms are created 
as a consequence of homologous recombination between the inverted repeats.  
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Table 1.1: Major BHV-1 genes discussed or investigated in this study (91, 99, 125, 132) 
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Figure 1.1: Schematic of the BHV-1 genome and the US2, US3, and US4 gene organization.   
Adapted from Takashima et al. (131) 
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The majority of proteins encoded by BHV-1 are involved in nucleic acid metabolism, 
DNA synthesis, and protein processing (115). Of the 33 structural proteins, 11 are glycoproteins 
(125). The major envelope glycoproteins are gB, C (gC), and D (gD) (5), and the minor 
glycoproteins include E (gE), G (gG), H (gH), I (gI), K (gK), L (gL), M (gM), and N (gN). Some 
of these glycoproteins play essential roles in viral pathogenicity and viability, as they regulate 
virus attachment, entry, egress, and cell to cell spread of the virus (28, 110, 125).  The five 
glycoproteins that are essential for growth in cell culture are gB, gD, gH, gL, and gK (51). Other 
major structural and regulatory proteins include the capsid protein, VP5 (103); VP8 and VP16, 
which are involved in gene regulation (16, 138); VP22, which has been implicated in BHV-1 cell 
to cell spread (54); and bICP4 and bICP0, which are key regulatory elements of viral 
transcription (61). 
Surrounding the nucleocapid is a specialized electron-dense layer called the tegument 
that contains approximately 15 viral proteins (84). After fusion of the virus, the tegument 
proteins dissociate from the nucleocapsid and play important roles such as modulating the host 
immune response (62) and activating the viral replication cycle (16). After viral replication, these 
proteins have important roles in generating infectious progeny through various regulatory 
functions, which are not yet completely understood.   
1.3 Alphaherpesvirus replication cycle 
The alphaherpesvirus lifecycle is separated into the following stages: entry, uncoating, 
translocation to the nucleus, replication of the genome, packaging, nuclear egress, envelopment, 
tegumentation, and cellular egress (Figure 1.2). BHV-1 mediates attachment to permissive cells 
through gB, gC, and gD (72, 75). To facilitate entry, gC attaches to the heparin sulfate  
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Figure 1.2: Schematic of the alphaherpesvirus replication cycle. 
The alphaherpesvirus virus replication cycle includes entry, uncoating, translocation to the 
nucleus, replication of the genome, packaging, nuclear egress, envelopment, tegumentation, and 
cellular egress. This figure is used with permission from Thomas C. Mettenleiter (84). 
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proteoglycan residue on the surface of cells, and when deleted, attachment can be mediated 
through gB (72, 104). After attachment, viral fusion occurs though interaction of gD with the 
nectin 1 receptor (HveC) (19), likely in cooperation with either gB or gH/gL (51, 83). Although 
interaction of gD with nectin 1 is required for entry, a compensatory mutation in gH at amino 
acid (a.a.) residue 450 can rescue gD-deleted BHV-1 viruses (121). 
After fusion of the virus with the cellular membrane, many of the tegument proteins are 
dissociated from the capsid to play a variety of roles including facilitating degradation of host 
mRNAs (65) and priming the cell for viral replication (85, 86).  Of importance, BHV-1 VP16 
and its homologous protein in herpes simplex virus type 1 (HSV-1) dissociates from the 
tegument to transactivate immediate-early gene expression, likely in collaboration with VP8 (92, 
93, 157). After fusion, the capsid travels to the nucleus along microtubules until the viral DNA 
translocates through a nuclear pore. While most of the tegument proteins dissociate after fusion, 
some proteins remain with the capsid until it docks at the nuclear pore. Specifically, in 
pseudorabies virus (PRV), UL36, UL37, and US3 have been shown to remain with the capsid 
until docking at the nuclear pore occurs (38).  
Once the viral DNA enters the nucleus, it circularizes and the DNA is replicated and 
transcribed. The genome is replicated through a rolling-circle mechanism using both viral and 
cellular proteins (71). Similar to other alphaherpesviruses, the BHV-1 genome is transcribed in a 
cascade which results in immediate-early (IE), early (E), and late (L) viral mRNAs. The IE genes 
are transcribed immediately after infection by host transcription factors which are enhanced by 
VP16 and VP8 (84, 126). The IE proteins are then shuttled into the nucleus to transcribe the E 
mRNAs. Following this, the E mRNAs are shuttled into the cytoplasm for translation before the 
resulting proteins are shuttled back into the nucleus for trans-activation of the L genes. Once the 
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L proteins are translated, they are translocated back into the nucleus where the capsid 
autocatalytically assembles and encapsulates the viral DNA (84, 85).   
 All Herpesviridae undergo a series of budding and de-envelopment events to acquire the 
tegument proteins and the cellular derived viral membrane (85, 86). Nuclear egress is a 
complicated process which requires the capsid to first bud through the inner leaflet of the nuclear 
membrane, a step called primary envelopment. Viral proteins UL31 and UL34 are essential for 
this process and deletions in either of these genes results in the accumulation of capsids in the 
nucleus of HSV-1 infected cells (116). In addition to these proteins, cellular protein kinases and 
US3 have been shown to aid in primary envelopment, possibly through phosphorylation (112, 
128). 
  After primary envelopment, the capsid buds through the outer nuclear membrane in a 
process called de-envelopment.  This process involves fusion of the primary viral envelope with 
the outer nuclear membrane. De-envelopment releases the viral capsids into the cytoplasm. US3 
in HSV-1 plays an important role in this process since US3-deleted mutants have been shown to 
accumulate the virions in the perinuclear space (59, 111).  
Once in the cytoplasm, the virions undergo a secondary envelopment process where they 
acquire their tegument and envelope before cellular egress. Although complex and not well 
understood, the process of tegumentation is thought to be facilitated through a series of protein-
protein interactions which begins with UL36 (159). Two layers of the tegument are added, with 
some proteins being capsid-associated and others being membrane-associated. The viral 
glycoproteins are thought to be key players in this process, and in PRV, gE and gM have been 
demonstrated to be required for incorporation of the major tegument protein, UL49 (34). 
Similarly, in HSV-1, gE and gD are required to incorporate the UL49 protein (29). US3 has been 
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shown to be a component of primary and mature PRV and HSV-1 virions and remains tightly 
associated with the capsid during the process of tegumentation. It is thought that US3 may play a 
role in facilitating alphaherpesvirus egress from the nucleus, since US3-deleted PRV are 
impaired during secondary envelopment (39, 112).   
The glycoproteins and tegument proteins assemble with the capsid through vesicles of the 
trans Golgi network (85). The vesicles eventually comprise the envelope of mature virions. 
Recruiting and retaining the virions at Golgi-derived vesicles has been shown to depend on 
UL11 and gM (12, 20), with deletions in these genes in PRV causing large intracytoplasmic 
accumulations of capsids embedded in Golgi-derived vesicles (60). In BHV-1, UL3.5 has been 
shown to interact with VP16 for efficient secondary envelopment and release (33, 69). 
Once the virus has acquired its tegument and envelope, the virus is transported to the 
cellular membrane in a vesicle where it fuses with the plasma membrane and the virus is released 
through exocytosis. Alternatively, alphaherpesviruses can enter adjacent cells through cell to cell 
spread using gD and gE/gI (122, 135). 
1.4 Latency 
 As is a hallmark of all herpesviruses, BHV-1 establishes lifelong latency in its host 
following acute infection. The primary site for latency is the sensory neuron of the ganglia, into 
which the virus gains access to through cell to cell spread (51). The circularized genome is 
maintained extrachromosomally in latently-infected neurons through high expression of the 
latency-associated transcript (LAT) and open reading frame (ORF) E, which prevent apoptosis, 
transcription of other viral genes, and regulate the latency-reactivation cycle (45, 49, 51Jones, 
1990 #1305, 52).  
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 Environmental stressors on the host which result in increased cortisol levels and 
immunosuppression lead to virus reactivation and subsequent proliferative infection. Three 
factors are associated with reactivation from latency, which include decreased expression of 
LAT and ORF-E, productive viral gene expression, and infectious virus released from nasal or 
ocular orifices (51). 
1.5 Alphaherpesvirus US3 serine/threonine kinase 
US3 has been identified in both BHV-1 and HSV-1 as being a 58 kilodalton (kD) 
serine/threonine kinase (131), and along with UL13, is one of the two serine/threonine kinases 
present in alphaherpesviruses (114). The multifunctional protein is conserved amongst the 
alphaherpesviruses, with low amino acid similarity but high functional conservation (Table 2). 
Furthermore, the kinase domain contains two invariant residues which are conserved among US3 
orthologues and correspond to the adenosine triphosphate (ATP)-binding domains and the 
catalytic sites (22) (Table 2). Although the protein is non-essential for viral replication, it has 
proven to play key roles throughout the subfamily in viral fitness and pathogenicity. The US3 
protein has been studied extensively in PRV and HSV-1, but the specific roles that US3 plays in 
BHV-1 infection have not been elucidated.  
1.5.1 Function of US3 in HSV-1 and PRV 
 The roles that US3 plays in HSV-1 and PRV infections have been well-characterized. In 
HSV-1, US3 helps evade the antiviral host response through disrupted interferon signaling (73, 
106) and helps establish latent infections in the sensory ganglia of its host (4). HSV-1 US3 has 
also been shown to regulate viral gene expression through independent blocking of histone 
deacetylation (107). Nuclear egress in HSV-1 is facilitated by US3 (57, 97) through 
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phosphorylation of gB (153), which downregulates the surface expression of gB (55), resulting 
in decreased antigen presentation at the cell surface (44, 55). Kato et al. have determined a 
number of viral substrates for US3, which include UL34, ICP22, US9, and the major tegument 
protein, UL47 (57). Recently, US3 has been demonstrated to play a role in regulating the 
subcellular localization of UL47 (56). 
PRV US3 plays a role in the downregulation of MHC-I surface expression (23), and 
similar to HSV-1 US3, blocks apoptosis during infection (35, 149).  For the purposes of this 
review, only the functions that were investigated in BHV-1 during this project will be discussed. 
The role that US3 plays in PRV and HSV-1 virion morphogenesis has been studied 
extensively. US3 has been shown to play an integral role in viral egress from the nucleus after 
encapsidation. Nuclear egress is a multifaceted process which is mediated through US3 
phosphorylation of various cellular and viral proteins. Two of the major players in this process 
are the viral proteins, UL31 and UL34, which together form a transmembrane complex that 
facilitates primary envelopment and subsequent nuclear egress (57, 59, 96, 109). US3 
phosphorylation of these proteins in HSV-1 is regulated by the UL13 serine/threonine kinase, 
which uses US3 as a substrate (58). In recombinant HSV-1 viruses lacking the US3 gene, the 
UL31/UL34 complex appeared at the nuclear rim in punctuate patterns as opposed to the 
distributed phenotype seen during WT infection (58, 111). Through the generation of a kinase-
dead mutant or mutating the corresponding serine/threonine targets in UL34, Rychman and 
Roller showed that proper distribution of the HSV-1 UL34/UL31 complex is due to US3-
mediated phosphorylation of UL34 in specific cell types (117). 
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Table 1.2: Amino acid sequence similarities between various US3 orthologues 
The table denotes the amino acid similarities of the US3 ORF between various 
alphaherpesviruses and displays the homology of the kinase regions in parentheses. Homologies 
between BHV-1 US3 and other US3 homologues within the alphaherpesvirus subfamily have 
been circled. Table adapted from (22). 
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To further aid in primary envelopment of the virions, HSV-1 US3 has been shown to 
direct capsids to the inner nuclear membrane and facilitate budding through phosphorylation of 
nuclear membrane proteins. This process is facilitated through the phosphorylation of lamin A/C 
proteins which are present in the nuclear lamina, and also emerin, an inner nuclear membrane 
protein that interacts with lamins (22, 95). It has recently been demonstrated that 
hyperphosphorylation of emerin via US3, in collaboration with UL34, results in increased 
mobility of emerin in the inner nuclear membrane. This causes disrupted connections between 
emerin and lamin, ultimately resulting in the nuclear lamina becoming compromised, which 
allows the virus to bud into the perinuclear space (70, 94).  
A predominant phenotype of US3-deleted PRV and HSV-1 viruses is the accumulation of 
capsids in the perinuclear space in large inner membrane blebs due to impaired de-envelopment 
(59, 112, 148). This phenotype has also been observed in cells infected with Marek‟s Disease 
Virus (MDV) when US3 is deleted (124). In HSV-1, the phenotype is dependent on the catalytic 
region of US3, since kinase-dead mutants have the same phenotype as US3-deleted viruses 
(117). The mechanism behind impaired egress in kinase-dead mutants may be the lack of 
phosphorylation of gB, since gB is important in the fusion of the outer nuclear membrane with 
the envelope surrounding perinuclear HSV-1 virions (153). The model suggested by Wisner et 
al. is that US3 phosphorylates the cytoplasmic tail of gB in the virion and triggers fusion 
between the outer nuclear membrane and the virion envelope (153). 
Further to its role in nuclear egress, US3-mediated phosphorylation of the major 
antigenic epitope, gB, has also been implicated as a mechanism by which alphaherpesviruses 
evade the host immune response (7, 119). Cell surface expression of gB has been shown to 
directly correlate with cell lysis of infected cells (8). To prevent excess expression of gB at the 
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surface of infected cells, herpesviruses have developed an intricate system to recycle the protein 
from the surface through endocytosis after being modified into an active form (13). Typically, 
intracellular trafficking of gB occurs from the cytoplasm to the cell membrane, where it is 
recycled through endocytosis before being directed to the trans-Golgi network for viral envelope 
assembly. Endocytosis is dependent on two motifs that are present in the cytoplasmic tail of gB. 
These motifs are recognized by subunits of the clatherin adaptor protein (AP) which make up the 
endocytotic vesicles (10).  
Recent studies in HSV-1 have shown that US3 phosphorylates gB at threonine residue 
887 (Thr-887), and that this modification results in a conformational change that may increase 
recognition of the endocytosis motif by AP (55, 153). Through mutations at Thr-887 in gB and 
inactivation of US3, Kato et al. were able to demonstrate that the surface expression of gB is 
markedly increased in HSV-1 infected cells (55). These results support the hypothesis that US3 
phosphorylation of gB at residue Thr-887 is required for optimal endocytosis of gB from the 
infected cell surface. 
To determine the effect that US3 has on pathogenicity and replication of HSV-1 in vivo 
due to the down-regulation of gB at the cell surface, Imai et al. used recombinant HSV-1 
expressing mutated Thr-887 gB for infection in a mouse model (44). Consistent with previous 
studies, where a kinase-dead HSV-1 US3 mutant was used for infection, Imai et al. showed that 
mutating the US3 phosphorylation target on gB significantly reduced both viral titres and the 
development of herpes stroma keratitis and periocular skin disease in infected mice (118). 
Furthermore, this group also developed a monoclonal antibody which reacts specifically with 
phosphorylated Thr-887 and was able to demonstrate that endocytosis of gB from the cell surface 
is dependent on phosphorylation at this residue. Taken together, these results show that the 
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phosphorylation of gB at residue Thr-887  by US3 is required for efficient down regulation of gB 
from the cell surface in HSV-1-infected cells, as well as for effective replication and 
pathogenicity in a mouse stromal keratitis model.  Follow-up studies by Imai et al. have 
characterized two other sequences that are necessary for optimal gB trafficking during HSV-1 
infection (43), which include tyrosine residue 889 (Tyr-889) and a dileucine residue at 871/ 872. 
The Tyr-889 residue was found to play the most critical role in regulating the intracellular 
transport of gB, expression of the protein on the surface of infected cells, and neurovirulence in 
mice.  
 US3 in HSV-1 and PRV has also been demonstrated to induce cytoskeletal 
rearrangements that result in actin stress fiber breakdown and long microtubule-rich extensions 
from the cell that can be several cell diameters in length (22). These extensions often make 
intimate contact with host cells, and in PRV, have been implicated in cell to cell spread of the 
virus (30). Through transfection assays, Van Minnebruggen et al. have demonstrated that in 
PRV, cytoskeleton actin stress fiber breakdown is dependent solely on US3 (141). Van der 
Broeke et al. have shed some light on the mechanisms behind the dramatic alphaherpesvirus 
US3-mediated cytoskeleton rearrangements (136) by demonstrating that the p21-kinases play an 
essential roles in both actin stress fiber breakdown and filamentous process formation when 
phosphorylated (activated) by US3. The cellular p21-activated kinases are key regulators of 
Cdc42/Rac1 Rho GTPase actin-modifying signaling pathways. Using gene-knockout mouse 
fibroblast cells, the group identified two components of the pathway that are essential for either 
US3-mediated stress fiber breakdown or filamentous process formation. These constituents are 
PAK2 and PAK1, respectively. US3 has been implicated in other herpesviruses as the main 
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driver of cytoskeleton rearrangements during viral infection, including BHV-5, herpes simplex 
viruse 2 (HSV-2), and most recently, BHV-1 (14, 32, 68).  
Interestingly, US3 and UL47 have recently been shown to reciprocally regulate their 
subcellular location within HSV-1 infected cells (56). Typically in HSV-1 infection, UL47 
shuttles between the nucleus and the cytoplasm to carry out various functions, including shuttling 
mRNAs into the nucleus during early infection (24) Through a systematic process of mutating 
serine and threonine residues near the nuclear localization site, serine at residue 77 (Ser-77) was 
shown to be phosphorylated by US3 and mutation of this residue resulted in accumulation of 
pUL47 at the nuclear rim of infected cells. Conversely, mutating the catalytic region in US3 had 
a similar phenotype. Pathogenesis studies showed that mutating either Ser-77 in UL47 or the 
catalytic site in US3 resulted in decreased viral replication and the development of herpes 
stromal keratitis in a mouse model. Furthermore, the nuclear localization of US3 was shown to 
be impaired in the absence of UL47 (43). These results demonstrate an important role for HSV-1 
US3 in both the phosphorylation and intracellular localization of the major tegument protein, 
UL47, and a role for US3 in the pathogenesis of HSV-1.  
1.5.2 Putative functions of US3 in BHV-1 
1.5.2.1 Known substrates  
Although much is known about the functions of US3 during HSV-1 and PRV infections, 
the role(s) that this protein plays in BHV-1 infection has not been fully characterized. The first 
report that identified BHV-1 US3 as a 58kD serine/threonine protein kinase demonstrated that 
unlike the orthologous protein in HSV-1 and PRV, BHV-1 US3 is not directly involved in 
blocking apoptosis in infected cells (131). Labiuk et al. recently identified VP8 and VP22 as 
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substrates of BHV-1 US3 (66, 67). The tegument protein, VP22, was shown to be 
phosphorylated by BHV-1 US3 as well as by the cellular casein kinase 2 (CK2). VP22 plays 
essential roles in the fitness of BHV-1 in vitro, including trafficking from infected to non-
infected cells in the absence of other viral proteins (41, 74). In addition to identifying VP22 as a 
minor substrate for US3, Labiuk et al. determined the catalytic region in the protein and 
determined that US3 autophosphorylates itself (66).  
Like in HSV-1, the BHV-1 UL47 gene product, VP8, is phosphorylated by US3 (67). 
Similar to its role in HSV-1, BHV-1 VP8 shuttles between the nucleus and cytoplasm and may 
bind viral mRNA (24, 25, 138, 145), while playing an important role in immunogenicity (131). 
Through a combination of immunoprecipitation and mass spectroscopy, Labiuk et al. were able 
to identify two kinases which contribute to the phosphorylation of VP8. US3 was found to play a 
minor role and CK2 was demonstrated to play a major role in the phosphorylation of VP8 (67). It 
is still unknown whether phosphorylation of VP8 in BHV-1 regulates its intracellular localization 
as has been demonstrated in HSV-1. 
Recently, using a recombinant baculovirus, BHV-1 US3 was shown to produce 
cytoskeleton changes in transfected cells that are characteristic of BHV-1 infection. These 
cytoskeleton modifications are similar to those seen in HSV-1 and PRV, which are dependent on 
the activity of US3. In the study by Brzozowska et al., microtubule-rich projections were formed 
in both BHV-1-permissive and non-permissive cells following transfection with the US3-
expressing baculovirus (14). Using confocal microscopy, the group was able to identify US3 
localizing in the nucleus early after transduction and throughout the cytoplasm as time 
progressed. Mutating the catalytic region in US3 demonstrated that the kinase activity is required 
for modification of the cytoskeleton in this system. It still remains to be elucidated whether 
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cytoskeleton remodeling in the context of BHV-1 infection is dependent on US3 and whether 
there are other viral proteins involved.  
Additional functions that BHV-1 US3 plays in vitro were recently elucidated (90) in an 
attempt to determine the role that it plays in the pathogenicity of BHV-1. To investigate this, the 
Schönböken and Aus12 strains were compared, which are low and high passage number, 
respectively. The objectives of this study were to compare the growth characteristics of the two 
virus strains, determine the significance of the aminoterminal domain of US3, and the subcellular 
location of US3-deleted BHV-1 virions. The role that BHV-1 US3 plays in apoptosis was also 
investigated and the function of the cellular SET protein in productive BHV-1 infection was 
observed. When the US3 gene was deleted in the highly passaged strain (Aus12), the group 
observed a large defect in cell to cell spread while the minimally passaged strain (Schönböken) 
had a minimal defect in cell to cell spread. It was hypothesized that point mutations elsewhere in 
the genome in the Schönböken strain had complemented the inhibitory effects of the US3 
deletion. Growth characteristics were slightly impaired (about a 10-fold difference) with the US3 
deleted viruses compared to their wild-type parent virus, but were independent of the strain used 
(i.e. Schönböken vs Aus12). Interestingly, ultrastructural analysis showed that US3-deletion 
results in nuclear accumulation of aggregates which contain viral nucleocapsids. This nuclear 
accumulation of nucleocapsids is distinct from the perinuclear accumulation of nucleocapsids 
that is seen in HSV-1, PRV and MDV (59, 96, 112, 124, 153), and may elude to a different mode 
of egress facilitated by BHV-1 US3.   
Recent studies on BHV-1 US3 have therefore shown the significance during viral 
infection (22). While BHV-1 US3 has been shown to be non-essential, it has a substantial impact 
on the growth kinetics and possibly cell to cell spread of the virus. Distinct functions of US3 in 
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the cell and its interactions with other viral proteins need to be elucidated to determine the exact 
role of US3 in BHV-1 pathogenesis. Expression kinetics of major structural and regulatory 
proteins and mature virion composition assays will be useful in determining which proteins may 
be affected and/or involved in the phenotypical changes that are seen upon US3 deletion in 
BHV-1. Kinetics assays will also help to determine at which stage in the viral cycle these 
phenotypical changes arise. Furthermore, confocal microscopy using antibodies against 
important proteins identified may elucidate a role for US3 in the viral lifecycle of BHV-1.  
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2.0 HYPOTHESIS AND OBJECTIVES 
 
Based on previous work on the role(s) of US3 serine/threonine kinase homologues during 
alphaherpesvirus infection, our hypothesis is that BHV-1 US3 contributes to viral fitness in vitro. 
To validate this hypothesis, five main objectives were explored. 
The first objective was to generate a US3-deleted and subsequent US3-rescued BHV-1 
virus. This was carried out using a homologous cloning strategy with a BHV-1-containing BAC. 
The second objective of this project was to characterize growth properties of the mutant 
viruses by performing a single-step growth assay. This standard growth assay was used to 
determine whether BHV-1 US3 plays a role during in vitro growth kinetics. 
Our third objective was to evaluate the effect of BHV-1 US3-deletion on the expression 
kinetics of major structural and regulatory BHV-1 proteins. This was carried out in an effort to 
identify the role that BHV-1 US3 plays on the expression of key viral proteins in vitro. 
Identifying proteins which are affected by US3-deletion also helps to identify roles that BHV-1 
US3 plays in the viral lifecycle.  
Our fourth objective was to characterize the composition of the mutant virions. This 
assay was used to identify putative roles that BHV-1 US3 may play in tegument acquisition and 
maturation of the BHV-1 virion in general. 
The fifth objective of this project was to identify viral process(es) impaired by US3-
deletion and other proteins which may be involved. This was a broad objective, which allowed 
us to explore potential roles that BHV-1 US3 may play in the viral lifecycle. The effect that 
BHV-1 US3 has on cellular morphology during infection was explored along with the role that 
the protein plays in cell to cell spread of BHV-1. Lastly, the role that US3 plays in the cellular 
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localization of -tubulin, gB, and substrates VP22 and VP8, during BHV-1 infection was 
determined.  
 
 
 
 
 
 
27 
 
3.0 MATERIALS AND METHODS 
 
3.1 Cloning 
3.1.1 Construction of ΔUS3 pBHV-1 BAC 
 To generate a ΔUS3 BHV-1, a 2-step PCR strategy was used to generate the knockout 
fragment, along with a homologous recombination system in DH10b cells which harbored the 
Colorado-1 strain (Cooper) bacterial artificial chromosome (BAC) (76) (Figure 3.1). The first 
step of the strategy was to PCR-amplify the 1246 bp kanamycin resistance cassette from pUC4K, 
and fragments upstream (325 bp) and downstream (470 bp) of US3 in pCooper BAC. Primers 
kan-F and kan-R (Table 3.1) were used to amplify the kanamycin cassette, primers US3up-F and 
US3up-R (Table 3.1) were used to amplify the upstream cassette, and primers US3down-F and 
US3down-R (Table 3.1) were used to amplify the downstream cassette. The resulting cassettes 
contained ~50 bp of homology to the kanamycin cassette. All cassettes were amplified using 500 
ng of the template plasmid on the PTC-225 Tetrad DNA Thermal Cycler (MJ Research) using 
the PCR program outlined in Table 3.2. The cassettes were then gel-purified using the QIAquick 
Gel Extraction Kit (Qiagen) according to the manufacturer‟s instructions. The full-length linear 
transgene (2041 bp) was generated by using all three cassettes and two primers which bind to the 
outside of either the upstream fragment (US3up-F) or the downstream fragment (US3down-R) 
(Table 3.1). The resulting 2041 bp fragment was gel purified as described above and used for 
homologous recombination. 
 The homologous recombination system used in this study included E. coli DH10B cells 
containing the pCooper BAC which harbors the green fluorescent protein (GFP) and 
chloramphenicol resistance cassettes. The pML300 plasmid, which contains the proteins 
necessary for homologous recombination, was used to transform DH10B cells by electroporation  
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Figure 3.1: Generation of a ΔUS3 pBHV-1 mutant. 
The kanamycin-containing linear transgene was initially generated through a 2-step PCR 
strategy. The linear transgene was then used to transform electrocompetent DH10b cells 
containing the lambda-red-expressing pML300 maintained at 30˚C. Homologous recombination 
was induced between the linear transgene and the WT US3 gene in WT pBHV-1 BAC through 
the addition of 0.2% L-rhamnose. The resulting ΔUS3 pBHV-1 clones were selected on 50 
g/ml kanamycin.  
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in a 1 mm cuvette (Sigma) using the Gene Pulser XCell (BioRad) at the following settings: 2.5 
kV, 25 F, and 200 Ω. pML300 harbors the recombinase driven, temperature sensitive, 
rhamnose inducible PrHaB-gbexo promoter. The PrHaB-gbexo promoter controls the lambda-red 
genes and is inhibited by glucose. pML300 is permissible at 30˚C and is spectinomycin 
selectable. 
 To isolate a ΔUS3 pBHV-1 BAC clone, electrocompetent DH10b cells harboring both 
the pCooper BAC and pML300 were transformed with the 2041 bp linear transgene, and 
recombination was induced through the addition of 0.1% rhamnose to activate the lambda-red 
genes on pML300. Throughout the course of these studies, all DH10b cells harboring pML300 
were grown at 30˚C to ensure that pML300 was maintained.  
 To select for the ΔUS3 pBHV-1 BAC clones, cells that were transformed with the linear 
transgene were plated on 25 g/ml chloramphenicol to select for the BAC, 50 g/ml 
spectinomycin to maintain pML300, and either 50 g/ml or 15 g/ml of kanamycin to select for 
ΔUS3 clones and determine which concentration was more suitable for selection. 50 g/ml of 
kanamycin was able to inhibit bacteria not possessing the kanamycin-resistance cassette. Four 
ΔUS3 clones were isolated and used for Western Blot analysis, PCR amplification of the mutated 
region, and sequencing to determine the integrity.  
 3.1.2 Construction of US3R pBHV-1 BAC 
 To generate a US3R BHV-1 using the ΔUS3 BHV-1 mutant, the en passant mutagenesis 
strategy (134) was performed. This strategy has been used extensively in the field to generate 
point mutations, substitutions, deletions, and insertions in BAC DNA.  The approach uses the 
inducible homing endonuclease, I-SceI, to induce site-specific cleavage of sequences containing 
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the 18 bp I-SceI recognition site (154). The strategy involves first generating a PCR product 
containing a positive selectable marker adjacent to an I-SceI recognition site and by regions of 
≥50 bp homology. The PCR product can then be inserted into the BAC through lambda-red 
recombination. After insertion, the positive selection marker can be excised by inducing the I-
SceI enzyme which will cleave the SceI site present in the insert. After cleavage, homologous 
recombination between the two flanking regions of the insert can be induced by induction of the 
lambda-red system (134). The GS1783 cell line used in this system was kindly given to our lab 
by Dr. Benedikt Kaufer in Berlin, Germany. This cell line has been used successfully in Dr. 
Kaufer‟s lab to generate insertions and deletions in BACs containing MDV clones.  
 The en passant mutagenesis strategy was used to rescue the original US3-deleted clone 
using the newly-obtained GS1783 cell line (Figure 3.2). The GS1783 cell line harbours the 
inducible (at 42˚C) lambda-red system and the inducible (via 0.1% L-arabinose) I-SceI enzyme. 
It is a derivative of the DY380 strain, which was used previously. To generate the US3R pBHV-
1 BAC clone, a 2.9 kB linear transgene was first generated from pRescue-zeo (see Figure 3.2) 
which was kindly provided by Dr. Robert Brownlie. The insert was isolated through PCR 
amplification using primers pRescue-F and pRescue-R (Table 3.1), Dpn-1 (New England 
Biolabs)-treated, and gel purified (QIAquick Gel Extraction Kit) to ensure that that the template 
(pRescue-zeo) was removed to prevent contamination. The linear transgene contains the zeocin 
cassette adjacent to the I-SceI recognition site and is flanked by the US3 region which was 
removed in the ΔUS3 pBHV-1 BAC. The flanking regions, containing 300 bp of identical 
sequences, were used to facilitate homologous recombination and subsequent resolution of the 
inserted region to generate a US3R pBHV-1 BAC clone.  
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Figure 3.2: ΔUS3 pBHV-1 rescue using the en passant mutagenesis strategy (134). 
A) The pRescue-zeo plasmid was generated which contains the zeomycin (zeo) cassette adjacent 
to the unique restriction site, SceI. The zeo cassette is flanked by redundant sequences (“A”) and 
the deleted regions of US3. The distant ends of the fragment correspond to the WT US3 
upstream and downstream regions that are present in the ΔUS3 pBHV-1 BAC (black squares). 
B) The linear rescue fragment was isolated from the vector through restriction digestion and used 
to transform electrocompetent, recombination-ready DH10b E. coli cells containing the ΔUS3 
pBHV-1 BAC. C) Homologous recombination between the linear transgene from pRescue-zeo 
and the ΔUS3 pBHV-1 BAC was induced and recombinants were checked for integrity. D) The 
isolated Rescue-zeo pBHV-1 BAC clone was used to transform electrocompetent GS1783 E. coli 
cells. E) The WT US3 gene was resolved (F) through induction of the I-SceI enzyme by 0.2% L-
arabinose and heat-shock at 42˚C to induce the lambda-red genes. 
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The overall rescue procedure included first electroporating the original ΔUS3 pBHV-1 
BAC clone with the purified linear transgene present in DH10b cells containing the pML300 
cassette, used previously. Briefly, rescued clones were selected on 25 g/ml chloramphenicol to 
maintain the BAC and 25 g/ml zeocin (Invitrogen) to select for the insert. Resulting clones 
were also counter-selected on 50 g/ml of kanamycin to ensure that the kanamycin resistance 
cassette had been replaced and 100 g/ml ampicillin to ensure that there was no pRescue-zeo 
carry-over in the new clones. Four clones were isolated using the Qiagen Large Construct Kit 
(Qiagen) according to the manufacturer‟s instructions and verified through PCR amplification of 
the 2.9 kB linear transgene. The altered BACs were then used to transform electrocompetent 
GS1783 cells using a 0.1 cm cuvette (settings: 15kV/cm, 25 F and 200Ω) which were 
maintained at 30˚C. To resolve the WT US3 region, the GS1783 cells were exposed to 1% L-
arabinose to induce the I-SceI enzyme, followed by heat shock at 42˚C to induce the lambda-red 
genes and facilitate homologous recombination between the flanking regions. 
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Table 3.1: Primers used for PCR 
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Table 3.2: PCR program used for amplification of oligonucleotides 
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Figure 3.3: Maps of the altered US3 region in WT, ΔUS3, and Rescue-zeo pBHV-1.  
A) WT pBHV-1 US3 gene is flanked by the US2 and US4 genes in the unique short region of 
pBHV-1. B)  ∆US3 pBHV-1 has the US3 gene replaced with a kanamycin resistance cassette C) 
Rescue-zeo pBHV-1 has the kanamycin cassette from ΔUS3 pBHV-1 replaced with a zeocin 
cassette that is flanked by the WT pBHV-1 US3 gene. 
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3.1.3 Verifying mutant virus integrity 
 After the resolution step, the resulting clones were selected for on 25 g/ml 
chloramphenicol, and 25 g/ml zeocin. >90% of the resulting clones were zeocin sensitive, 
indicating that the WT US3 fragments had resolved. To verify that the WT fragments were 
intact, PCR-amplification of the 4kB US2-US3-US4 region was carried out and the clones were 
sent for sequencing of the region in the WT, ΔUS3 and US3R pBHV-1 BAC clones. Sequencing 
confirmed that the US2-US3-US4 region was intact in the rescued clone and did not have any 
point mutations compared to WT. Interestingly, sequencing of the full US2 region confirmed a 
guanine insertion which renders the open reading frame non-functional. This insertion was 
present in all 3 clones (WT, ΔUS3, and US3R), and is likely the result of cell-culture adaptation 
of the virus (78). 
 To ensure that no spontaneous recombination events occurred in the viral genome, 
restriction fragment length polymorphisms were detected through digestion with HindIII. 
Briefly, two T-150 flasks containing confluent Madin-Darby Bovine Kidney (MDBK) cells that 
were infected with BHV-1 viruses at a multiplicity of infection (MOI) of 1 were harvested after 
48 hours, or until cells showed significant cytopathic effects. Infected cells were scraped from 
the flasks and pelleted via low speed centrifugation, and the supernatants were collected. To 
concentrate the virus, supernatants were pelleted through a 30% (w/v) sucrose cushion in TNE 
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA) by ultracentrifugation using a 
Beckman S232Ti rotor at 24,000 rpm for 2 hours at 4˚C. After centrifugation, pellets were 
resuspended in 50 l TNE buffer overnight at 4˚C. To isolate the viral genome from each 
preparation, the Gentra PureGene Cell Kit (Qiagen) was used according to the manufacturer‟s 
directions. After isolation of the genome, 1.5 g of DNA from each suspension was digested 
38 
 
with HindIII (NEB) for 6 hours according to the manufacturer‟s directions. Following digestion, 
50 l of each sample was loaded on a 0.7% agarose gel containing 0.01% GelRed Nucleic Acid 
Gel Stain (Biotium) and fragments were electrophoretically separated at 35 volts (20 mAmps) 
for 18 hours. Fluorescent bands were detected using the Gel Doc XR+ System (BioRad) after 
post-staining with GelRed (Biotium). 
 3.2 Propagation and titration of viruses in cell culture 
 WT, ΔUS3 and US3R pBHV-1 BACs were isolated using the QIAGEN Large-Construct 
Kit (Qiagen), according to the manufacturer‟s instructions. All isolated pBHV-1 BACs were then 
used to transfect Fetal Bovine Testicular (FBT) cells. Briefly, varying concentrations of pBHV-1 
BAC DNA and Lipofectamine 2000 (Invitrogen) were mixed according to the manufacturer‟s 
instructions, and allowed to interact at room temperature for 45 minutes. After incubation, the 
mixture was diluted in 50% reduced serum Minimal Essential Medium (MEM) (Invitrogen) and 
added to 80% confluent FBT cells in 6-well nunc assay plates (BD Falcon). The cells were 
incubated at 37˚C/5% CO2 overnight to allow the DNA to enter the cells. The next morning, the 
DNA-containing medium was replaced with MEM with 10% fetal bovine serum (FBS). 
Transfection efficiency was determined at 48 hours post-transfection under the fluorescence 
microscope which detected the GFP in the virus. 
 At 72 hours post-transfection, or when the cell monolayers showed significant signs of 
BHV-1 infection, the monolayers were collected and frozen at -80˚C. After two freeze-thaw 
cycles and low-speed centrifugation, the virus-containing supernatants were collected and used 
to propagate the virus in MDBK cells. After viral propagation, stocks were either frozen at -80˚C 
or titred under overlay medium in 24-well Nunc assay plates (BD Falcon) containing 2x MEM 
(Gibco) with 2% FBS and 0.8% agarose type VII (Sigma-Aldrich).  
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3.3 Single-step growth curves 
 To investigate the growth kinetics of the viruses, MDBK cells were infected at a MOI of 
5 in 35-mm cell culture dishes. Extracellular and intracellular fractions were isolated from each 
infection from 5-25 hours at 5 hour intervals. After the intracellular fractions were put through 
two freeze-thaw cycles, all samples were clarified via low-speed centrifugation. The resulting 
supernatants were frozen at -80˚C before being titred in MDBK cells under overlay medium as 
described previously (77).  
3.4 Expression kinetics assay 
3.4.1 Preparation of BHV-1 infected cell lysates 
 MDBK cells were either mock-infected or infected at MOI of 2 in T-25 flasks. Cells were 
harvested at 5-25 hours post-infection at 5-hour intervals by scraping the cells from the flasks 
with a rubber scraper. Cells were washed two times in ice-cold phosphate buffered saline (PBS) 
(3 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, 8 mM Na2HPO4, pH 7.3),  and the pellets were 
resuspended in Triton-X phenylmethylsulfonyl fluoride (TX-PMSF) buffer (150 mM NaCl, 1 
mM EDTA, 1% Triton X-100, 50 mM Tris/HCL, pH 7.4) supplemented with 1mM PMSF, 1 
μg/ml aprotinin, 1 μg/ml leupeptin, and 1 mM dithiothreitol (DTT). Resuspended cells were 
incubated on ice for 30 minutes before centrifugation at 1600 RCF for 10 minutes at 4˚C to 
isolate the solubilised protein fraction.  
3.4.2 SDS-PAGE 
 After determining the amount of protein in each sample using the Bio-Rad Protein Assay 
Kit (Bio-Rad) according to the manufacturer‟s directions, equal amounts of each sample were 
denatured and resolved through a 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis 
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(SDS-PAGE) gel (10% bisacrylamide, 25% 1.5M Tris pH 8.8 (v/v), 0.1% SDS, 64.84% (v/v) 
ddH20, 0.05% APS, 0.01% TEMED) using 1.5 mm spacers with a 4% stacking gel (4% 
bisacrylamide, 25% (v/v) 0.5M Tris-HCL, pH 6.8, 0.1% SDS, 70.84% (v/v) ddH20, 0.05% APS, 
0.01% TEMED) in 1x SDS running buffer (0.3% (w/v) Tris, 1.44% (w/v) glycine, 0.1% (w/v) 
SDS). Samples were run at 110 volts for 2 hours to separate all proteins of interest. 
3.4.3 Western Blot 
 Proteins were electrophoretically transferred to a nitrocellulose membrane at 100 volts 
for 1 hour 10 minutes at 4˚C. Membranes were blocked in Odyssey Blocking Buffer (Li-Cor) 
diluted 1:1 in PBS for 2 hours at 4˚C with rocking. After blocking, membranes were incubated 
with primary antibodies overnight at 4˚C with rocking. Monoclonal antibodies (MAb) that were 
used included those against -tubulin (Sigma-Aldrich), -actin (Sigma-Aldrich), BHV-1 VP8, 
gC, gB, and gD. Polyclonal antibodies (PAb) that were used included those against BHV-1 US3, 
VP5, VP16, bICP4, and VP22. After thoroughly washing with PBS containing 0.1% Triton X-
100, membranes were incubated with IRDye 680-conjugated goat anti-mouse IgG or IRDye 
800CW-conjugated goat anti-rabbit IgG (Li-Cor). After thoroughly washing the membranes with 
PBS containing 0.1% Triton X-100, fluorescent bands were visualized using the Odyssey 
Imaging System and analyzed with the Odyssey 3.0.16 application software (Li-Cor). 
 Blots were re-probed up to two times by removing membrane-bound antibody complexes 
using the Newblot Nitro Stripping Buffer (Li-Cor) according to the manufacturer‟s instructions. 
Membranes were blocked in Odyssey Blocking Buffer (Li-Cor) for 2 hours before re-probing 
with new antibodies.  
3.5 Purification of BHV-1 viruses 
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 Nine to twelve T-150 flasks containing confluent MDBK cells were infected with WT, 
ΔUS3, or US3R viruses at 1x106 pfu/flask. After cells displayed complete cytopathic effect (~ 48 
hours post-infection), flasks were freeze-thawed twice to release intracellular virus. Cell debris 
were removed via low-speed centrifugation and supernatants were pelleted through a 30% (w/v) 
sucrose cushion in TNE buffer by ultracentrifugation using a Beckman S232Ti rotor at 24,000 
rpm for 2 hours at 4˚C. To further purify the viruses, the pellets were resuspended in TNE buffer 
overnight at 4˚C before being sonicated and gently layered onto a 10-60% (w/v) potassium 
sodium tartrate gradient in TNE buffer present in 36 ml tubes. The gradient was generated using 
a Hoefer SG50 Gradient Maker (Amersham). The tubes containing the gradients and virus 
suspensions were centrifuged for 2 hours at 25,000 rpm in the SW32Ti rotor. To remove the 
purified viral suspension from the gradient, the tubes were punctured in the side using a 21-
gauge needle and the thin virus-containing band was removed. Care was taken to avoid isolating 
any cell debris which trailed above the band containing the viral suspension. Purified virus was 
concentrated by resuspending in TNE followed by ultra-centrifugation at 25,000 rpm for 2 hours 
at 4˚ C in the SW32Ti rotor. After resuspending the concentrated, purified virus in TNE, samples 
were frozen at -80˚C. 
3.5.1 Normalization of the purified virus  
 To normalize the amount of the three purified virus samples (i.e. WT, ΔUS3, and US3R) 
used in subsequent Western Blot analyses, varying amounts of purified virus samples were 
loaded onto a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. Rabbit VP5-
specific serum (77) was used as the primary antibody and IRDYe 800CW-conjugated goat anti-
rabbit IgG was used as the secondary antibody for detection of VP5. Bands were visualized using 
the Odyssey Imaging System and analyzed using the corresponding 3.0.16 application software. 
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In addition to Western Blot analysis, a BCA Protein Assay (Thermo Scientific) was used to 
determine the protein concentration in each purified virus sample.  
3.6 Plaque-size quantification 
 To determine whether the ΔUS3 BHV-1 virus was impaired in cell to cell spread, a 
plaque-size analysis was performed for all viruses. Briefly, MDBK cells were cultured in six-
well plates and infected with 50-100 PFU/well of WT, ΔUS3, or US3R BHV-1 viruses. After 48 
hours, or until distinct plaques had formed, cells were fixed with a solution containing 75% 
ethanol and 25% glacial acetic acid. Following fixation, infected cells were stained using a 
cocktail of gB-specific MAbs, followed by incubation with alkaline phosphatase-conjugated goat 
anti-mouse IgG (Kirkegaard and Perry Laboratories). After washing, plaques were visualized by 
incubating cells with 5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium 
(BCIP/NBT) (Sigma). 
 To quantify plaque sizes, 50 discrete images of plaques were acquired using the Zeiss 
Axiovert 200M microscope. The average plaque diameters were calculated using the AxioVision 
AC 4.5 Software to make two perpendicular diameter measurements of each plaque. The plaque 
sizes were then ranked between all viruses and statistical analysis was performed using 
GraphPad Prism 5 software (GraphPad).  
3.7 Light microscopy of BHV-1 infected MDBK cells 
  The morphologies of virus-infected cells were examined by light microscopy. MDBK 
cells were infected with each virus at MOIs from 2-5 and images were acquired from 5-35 hours 
post-infection with the Zeiss Axiovert 200M microscope.  
3.8 Confocal microscopy of BHV-1 infected MDBK cells 
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 MDBK cells grown on two-chamber Permanox slides (Lab-Tek) were infected with 
either WT or ΔUS3 BHV-1 at MOI of 3. At various times post infection, cells were fixed with 
4% paraformaldehyde for 15 minutes at room temperature followed by blocking with 5% heat-
inactivated goat serum in PBS with or without 0.1% Triton X-100 to permeabilize the cells. Cells 
were incubated with primary antibody and after washing, incubated with either Alexa Fluor 633 
goat-anti rabbit IgG or Alexa Fluor 488 goat anti-mouse IgG (Invitrogen). 0.1% Triton X-100 
was added to the staining solutions to permeabilized cells when necessary. Cells were air-dried 
overnight at room temperature in the dark and mounted the next day using Prolong Gold 
Antifade Reagent with Dapi (Invitrogen). Images were acquired using normalized settings on 
either the Zeiss LSM410 or the Leica DMI6000 confocal microscopes and enhanced under 
identical parameters using the ImageJ software system. 
3.9 Fluorescence-Activated Cell Sorting (FACS) 
 The effect that US3 has on the total and cell surface expression of BHV-1 gB was 
analyzed by FACS. Briefly, MDBK cells were infected at an MOI of 3 and harvested at 4 hours 
post-infection by trypsinization and washed three times in ice-cold PBS. A cell suspension of 
1x10
7
 cells/ml was generated, and 50 μl of cells were aliquoted into a 96-well round-bottom 
plate (Corning). To investigate the cell surface expression of gB, cells were blocked in 5% goat 
serum in PBS for 20 minutes at 4˚C. Cells were then incubated with gB-specific mouse IgG2a 
MAb (1:2000 dilution) for 20 minutes at 4˚C, followed by incubation with Alexa Fluor 633 goat 
anti-mouse IgG (Invitrogen) (1:2000 dilution) for 20 minutes at 4˚C. Each step was followed by 
thorough washing in PBS. Finally, cells were fixed with 2% formaldehyde.  
To detect total gB expression in infected cells, cells were initially fixed and 
permeabilized using the BD Cytofix/Cytoperm Plus kit (BD Bioscience) according to the 
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manufacturer‟s protocol. Following fixation, cells were blocked in 5% goat serum in PBS for 20 
minutes at 4˚C. After blocking, cells were incubated with gB-specific mouse IgG2a MAb 
(1:2000 dilution) for 20 minutes at 4˚C, followed by incubation with Alexa Fluor 633 goat anti-
mouse IgG (Invitrogen) (1:2000 dilution) for 20 minutes at 4˚C. Since cell permeabilization is 
not stable, all washes and incubations were performed in the presence of a saponin-containing 
buffer included in the BD Cytofix/Cytoperm kit. After the final wash, cells were resuspended in 
PBS.  
To ensure non-specific binding of the primary antibody did not result in false readings, 
purified mouse myeloma IgG2a (Invitrogen) was used as an isotype control. All samples were 
read on a FACSCalibur flow cytometer (BD Bioscience) and analyzed using Cell Quest software 
(BD Bioscience).  
4.0 RESULTS 
4.1 Construction and verification of ΔUS3 and US3R pBHV-1  
 To construct a ΔUS3 BHV-1 virus (Cooper-1 strain), a bacterial homologous 
recombination strategy was used. Briefly, DH10B cells containing pCooper in BAC (76) and the 
pML300 plasmid harboring the inducible lamda-red recombination cassette were electroporated 
with a 2.0 kB fragment that contained the full-length BHV-1 US3 cassette with sequences 
upstream and downstream to facilitate homologous recombination. The fragment was generated 
through a 2-step PCR strategy. After homologous recombination and recovery, DH10b cells 
were plated on chloramphenicol to select for the BAC, spectinomycin to maintain pML300, and 
kanamycin to select for the ΔUS3 recombinant BACs (Figure 3.1). Over 100 kanamycin-
resistant colonies resulted from the recombination event, showing that homologous 
recombination using this system was highly effective.  
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To ensure that the phenotype of the ΔUS3 clones was due to US3 deletion alone, a US3R 
virus was generated. Briefly, a two-step en passant mutagenesis procedure was undertaken, 
which first replaced the kanamycin-resistance cassette in the ΔUS3 clone with a linear transgene 
containing the full-length US3 gene and a zeocin cassette, and second, resolved the WT US3 
gene (134) (Figure 3.2). To ensure that a scar-less rescue would occur, an inducible SceI site 
(154) was incorporated upstream of the zeocin cassette in the linear transgene which, when cut, 
would result in homologous recombination between ~300 bp identical US3 sequences 
immediately upstream and downstream of the zeocin cassette. To replace the kanamycin-
resistance cassette in the ΔUS3 clone, the zeocin-resistant linear transgene was amplified from 
pRescue-zeo (see Figure 3.2) and used to transform electrocompetent and recombination-ready 
DH10b cells containing pML300 and the ΔUS3 pBHV-1 BAC.  
After selection on zeocin, the resulting pBHV-1 BAC was used to transform GS1783 
cells. GS1783 cells contain the inducible lambda-red genes and the SceI enzyme, and were used 
to resolve the WT US3 gene in the pBHV-1 BAC through restriction digestion of the linear 
transgene with I-SceI, followed by lambda-red induction and homologous recombination 
between identical sequences within the transgene. The resulting US3R pBHV-1 BACs were 
selected based on chloramphenicol resistance and zeocin sensitivity. 
 To verify the integrity of ΔUS3 and US3R BHV-1, PCR analysis, sequencing, restriction 
digestion, and Western blotting using anti-US3 antibodies were carried out. Sequencing of the 
4kB US2/US3/US4 region in the WT, ΔUS3, and US3R pBHV-1 showed that ΔUS3 pBHV-1 
had no unexpected mutations and US3R pBHV-1 had reverted to an identical genotype 
compared to WT pBHV-1. Furthermore, sequencing elucidated that an insertional mutation was 
present in the US2 region in all clones, including WT pBHV-1. This may be due to the Cooper 
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strain‟s adaptation to cell culture, as US2 has been previously shown to be non-essential for 
HSV-1 growth under these conditions (78). 
 To verify that the ΔUS3 BHV-1 was only manipulated in the US3 region of the genome, 
restriction profiling was done using HindIII digestion on purified viral DNA. As demonstrated in 
Figure 4.1, the WT and US3R clones had restriction profiles which were identical to each other 
and representative of the expected WT profile as determined by Clone Manager 9 Professional 
Edition software program (Sci-Ed). The ΔUS3 BHV-1, on the other hand, had the expected 
restriction profile that corresponded to two different bands at 8231 bp and 6307 bp compared to 
WT or US3R BHV-1. 
To verify that the ΔUS3 BHV-1 does not express US3 and that the US3R does, Western 
blot analysis was conducted by generating whole-cell extracts from infected MDBK cells and 
probing with a US3-specific rabbit PAb. As expected, the WT and US3R BHV-1 both expressed 
US3 during viral infection, whereas the ΔUS3 BHV-1 does not produce the 58 kD protein during 
infection (Figure 4.2). These results confirmed the integrity of the ΔUS3 and US3R BHV-1 
clones. 
4.2 Single-step growth curves of WT, ΔUS3 and US3R BHV-1 
 To investigate the growth kinetics of the WT, ΔUS3 and US3R BHV-1, a single-step 
growth assay was carried out. MDBK cells were infected at an MOI of 5 and harvested from 5-
25 hours post-infection. Intracellular and extracellular viral titres were determined by quantifying 
plaque formation under BHV-1 neutralizing serum. Figure 4.3 a,b is a compiled figure 
containing the single-step growth curves from the three viruses titred in quadruplicate and is 
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Figure 4.1: HindIII-digestion of ΔUS3, WT and US3R BHV-1.   
Viral DNA preparations were digested with HindIII for 6 hours at 37˚C before being run on a 
0.7% agarose gel for 18 hours at 35 volts (20 mAmps). The gel was then stained with GelRed 
Nucleic Acid Gel Stain (Biotium) for 30 minutes. Bands were visualized using the Gel Doc XR+ 
system (Bio Rad).  
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Figure 4.2: US3 expression profiles of WT, ΔUS3 and US3R BHV-1 infected cells. 
MDBK cells were infected at an MOI of 2 for approximately 24 hours. Whole-cell extracts were 
prepared and low-speed centrifugation was used to collect the solubilised proteins. Equal 
amounts of total cell lysates were analyzed by Western blot using US3-specific PAbs. Proteins 
were visualized by probing with goat anti-rabbit IgG IRDye 680-conjugated secondary antibody 
(LI-COR Biosciences) and visualized using LI-COR‟s ODYSSEY infrared imaging system (LI-
COR Biosciences). 
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Figure 4.3 a, b: Growth characteristics of WT, ΔUS3 and US3R BHV-1.  
Duplicate cultures of MDBK cells were infected with each virus at an MOI of 5. Virus-
containing supernatants and infected cells were collected at 5-25 hours post infection at 5 hour 
intervals. The intracellular (a) and extracellular (b) titres of infectious progeny were determined 
using a standard plaque assay and BHV-1 neutralizing serum. Titres were determined based on 
plaque formation. The figures are representative of two independent experiments conducted 
under identical parameters.  
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representative of two independent experiments conducted previously. 
 The curves demonstrate that the growth kinetics of the ΔUS3 BHV-1 is impaired 
compared to both WT and US3R BHV-1, which are nearly identical. Both the intracellular and 
extracellular production of ΔUS3 BHV-1 was similar to that of WT until about 15 hours post-
infection. After this time point, the titres of the ΔUS3 BHV-1 plateaued during the remainder of 
the infection, staying close to ~10
6
 pfu/ml. This observed defect in growth kinetics of ΔUS3 
BHV-1 could be due to a deficiency in cell to cell spread or egress of the virus in vitro.  
4.3 Effect of US3 deletion on the expression kinetics of major BHV-1 proteins 
 An expression kinetics assay was carried out to investigate the effect of US3 deletion on 
major structural and regulatory BHV-1 proteins. Briefly, MDBK cells were infected at a MOI of 
2 to investigate the kinetics of the IE, E, and L BHV-1 proteins in infected cells. Infected cells 
were harvested from 5-25 hours post-infection at five hour intervals. Whole-cell lysates were 
generated and frozen at -80˚C. Protein samples were prepared and analyzed by Western blotting 
with antibodies against each of the BHV-1 proteins of interest. Bands were visualized using the 
Odyssey system (LiCor) and densitometry was carried out using the LiCor Odyssey software to 
quantify the amount of normalized proteins over time.  
The Western Blots shown in Figure 4.4 demonstrate a number of differences in protein 
expression between WT and the ΔUS3 BHV-1 infected cells. Any differences in protein 
expression between samples which were less than 1.5x were deemed not biologically significant. 
It was demonstrated in two independent experiments that compared to WT BHV-1 infected cells, 
VP5 was expressed in ΔUS3 BHV-1 infected cells at amounts that were approximately 5x higher 
early in infection and 1.5x higher at late points of infection; VP16 and VP8 were expressed at 
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amounts that were  approximately 1.5x  higher during late stages of infection; gC was expressed 
at approximately 2x lower amounts beginning at 15 hours post-infection, and although there was 
a reduction in protein expression at 15 hours post-infection, this was deemed to be an artifact of 
the gel; bICP4 expression was expressed at 2 hours compared to 3 hours post infection in WT 
BHV-1 infected cells, and was expressed at approximately 2x higher amounts from 1-10 hours 
post-infection; Total gB expression was almost 2x  that of WT BHV-1 at 10 hours post infection, 
but was approximately 1.5x lower during late stages of infection (15-25 hours post-infection), 
with levels decreasing over the course of infection; gD expression was detected earlier at 4 hours 
post-infection, and; VP22 expression was fairly consistent between both viruses. These data 
support a role for US3 in efficient protein expression and regulation during the course of 
infection. 
4.4 Effect of US3 on the protein composition of the mature virion 
To investigate the role US3 plays in the incorporation of BHV-1 proteins into mature 
virions, viruses were purified and analyzed by Western blotting for the presence of major BHV-1 
structural and regulatory proteins. Initially, WT, ΔUS3 and US3R BHV-1 were propagated in 
MDBK cells and purified using a 10-60% potassium sodium tartrate gradient. To determine the 
relative amounts of protein present in each purified virus sample, a BCA assay and Western Blot 
using a PAb against the capsid protein, VP5 were carried out. After the relative protein 
concentrations between the viruses were normalized, Western blots were run using antibodies 
against VP5, gB, gC, gD, VP16, VP8, VP22, and US3.  
Figure 4.5a is a composite from one independent experiment that includes all the bands 
of interest from each Western Blot, including densitometry results. Figure 4.5b is a graphical 
representation of the averaged relative protein differences between the WT and ΔUS3 BHV-1  
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Figure 4.4 a, b, c: Effect of BHV-1 US3 on viral protein expression during infection.  
A) MDBK cells were infected at a MOI of 2 and harvested at 5-25 hours post infection at 5 hour 
intervals. Equal amounts of total cell lysates were analyzed by Western blotting using PAbs 
specific for VP5, VP22, VP16, US3, or bICP4, and MAbs specific for gC, gB, gD, VP8, or -
actin. Proteins were visualized by probing with goat anti-rabbit IgG IRDye 680-conjugated 
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secondary antibody (LI-COR Biosciences) or with goat anti-mouse IgG IRDye 800CW-
conjugated secondary antibody and visualized using LI-COR‟s ODYSSEY infrared imaging 
system (LI-COR Biosciences). The numbers shown below each well represent the normalized 
fluorescence intensity of each sample relative to -actin as determined by densitometry using the 
ODYSSEY system software. All densitometry values were multiplied by 100. This figure is 
representative of two independent experiments conducted under identical parameters. B) 
Graphical representation of the normalized densitometry values of BHV-1 proteins early during 
infection (1-5 hours post-infection), and at late times post infection (10-25 hours post-infection), 
C).  
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a)                                                                           b) 
 
 
Figure 4.5 a,b: Effect of US3 on the mature virion composition of BHV-1.  
Viruses were purified and normalized based on the density of the major capsid protein, VP5. 
Volumes of solubilised proteins were loaded on a 10% SDS-PAGE gel and used for Western 
blot. A) Equal amounts of total cell lysates were analyzed by Western blotting using PAbs 
specific for VP5, VP22, or VP16 or MAbs specific for gC, gB, gD, or VP8. Proteins were 
visualized by blotting with goat anti-rabbit IgG IRDye 680-conjugated secondary antibody (LI-
COR Biosciences) or with goat anti-mouse IgG IRDye 800CW-conjugated secondary antibody 
and visualized using LI-COR‟s ODYSSEY infrared imaging system (LI-COR Biosciences). 
Densitometry was used to analyze the blots and normalized values are shown as percentages of 
the corresponding values for the WT virus (shown below each blot). B) Average densitometry 
results from two separate experiments using WT and ΔUS3 BHV-1.  
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from two separate experiments. Based on the Western blots, any difference determined by 
densitometry that was ≤ 20% was deemed to be not biologically relevant. Therefore, the 
observed difference in gC incorporation between WT and ΔUS3 BHV-1 was deemed to be non-
significant as were the differences in protein concentration between WT BHV-1 and US3R 
BHV-1. The order of greatest to smallest relative changes in protein incorporation between the 
WT and ΔUS3 BHV-1 viruses as shown in Figure 4.5b is VP8 (↓ 58%) > gB (↑ 54%) > VP16 (↓ 
53%) > VP22 (↑ 40%) > gD (↑ 23%) > gC (↓ 10%).  
4.5 The role of US3 in cell to cell spread 
To determine whether US3 in BHV-1 is required for efficient cell to cell spread, a 
plaque-size analysis was carried out using WT, ΔUS3 and US3R BHV-1. Briefly, cells were 
infected with each virus at 50-100 PFU/well and after ~48 hours, cells were fixed and probed 
with gB-specific MAbs followed by incubation with alkaline phosphatase-conjugated goat anti-
mouse IgG. Plaques were visualized using 5-bromo-4-chloro-3-indolylphosphate and nitroblue 
tetrazolium and plaque size diameters were quantified and ranked before statistical analysis was 
done. 
As shown in Figure 4.6, the mean plaque diameters resulting from ΔUS3 BHV-1 
infection were significantly smaller than those caused by either WT or US3R BHV-1. 
Additionally, ΔUS3 BHV-1 had a larger number of small plaques compared to WT, which had 
greater number of larger plaques. The mean plaque diameters resulting from either WT or US3R 
BHV-1 infection were not significantly different. This study was repeated three times with nearly 
identical results, confirming that BHV-1 US3 is required for efficient cell to cell spread in vitro.  
4.6 Effect of US3 on infected monolayers during BHV-1 infection in vitro 
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Figure 4.6: Effect of US3 on cell to cell spread in vitro.  
MDBK cells were infected WT, ΔUS3 or US3R BHV-1 and incubated under semisolid medium 
for ~48 hours. Once plaques had formed, cells were fixed with ethanol-acetic acid and plaques 
were detected using a gB-specific MAb. The mean diameters of 50 plaques were photographed 
and quantified using AxioVision AC 4.5 Software (Zeiss). The plaque sizes were then ranked 
before a two-tailed t test was carried out using Prism 5 software.  
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In addition to US3 in other alphaherpesviruses (68, 136), BHV-1 US3 has been shown to 
be responsible for cellular cytoskeleton reorganization outside of the infection context (14). To 
determine whether US3 is responsible for morphological changes which are indicative of 
cytoskeleton reorganization in the context of infection, MDBK cells were infected at an MOI of 
2 with WT, ΔUS3 and US3R BHV-1, and examined under phase-contrast microscopy after 10 
hours of infection. As shown in Figure 4.7, WT and US3R BHV-1 caused identical 
morphological changes to the host cell, whereas infection with ΔUS3 BHV-1 resulted in a 
different phenotype.   
To investigate the in vitro kinetics of the US3-dependent cytoskeleton reorganization, 
MDBK cells were infected at an MOI of 5 with WT or ΔUS3 BHV-1 and examined under phase-
contrast microscopy from 5-35 hours post-infection at 5 hour intervals. As shown in Figure 4.8, 
infection with ΔUS3 BHV-1 likely results in the abolishment of cellular adhesions compared to 
WT BHV-1 starting as early as 15 hours post-infection. This effect was delayed until ≥35 hours 
post infection in cells infected with a MOI of 0.1 (results not shown), demonstrating that US3-
dependent morphological changes in BHV-1-infected cells is dependent on the amount of US3 
protein present in the cell, which can be manipulated by either increasing the length of infection 
or by increasing the viral load. 
4.7 Effect of US3 on the subcellular localization of tubulin, VP22, VP8, and gB 
Since BHV-1 VP22 (66), BHV-1 VP8 (67), and HSV-1 gB (55) have been shown to be 
substrates for US3, the subcellular localization of these proteins were studied in the absence of 
US3 in BHV-1infected MDBK cells. Initially, US3 was investigated by infecting MDBK cells in 
2-well chamber slides at an MOI of 3. This MOI has been used and balances the integrity of the 
monolayer while allowing for viral protein expression within a short time frame. 
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Figure 4.7: Deletion of US3 influences cell morphology in BHV-1 infected MDBK cells.  
MDBK cells were infected with WT, ΔUS3 or US3R BHV-1 at a MOI of 2. Ten hours post-
infection, monolayers were visualized using a Zeiss Axiovision microscope.  
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Figure 4.8: US3-dependent changes in cell morphology occur over the course of infection.  
MDBK cells were either mock-infected or infected with WT or ΔUS3 BHV-1 at a MOI of 5 and 
examined using the Zeiss Axiovert 200M microscope from 5 to 35 hours post infection at 5 hour 
intervals. 
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At 4 hours post-infection, cells were fixed and US3 was detected with rabbit serum specific for 
BHV-1 US3. As shown in Figure 4.9, US3 was clearly nuclear 4 hours post-infection in WT 
BHV-1 infected cells, and was absent throughout the course of infection in either mock-infected 
or ΔUS3 BHV-1 infected MDBK cells. The nuclear expression of US3 is consistent with results 
by Labiuk et al. (66). 
To investigate the role that BHV-1 US3 plays in cytoskeleton reorganization, tubulin was 
stained with a specific MAb. As shown in Figure 4.10, a phenotypic difference in cellular 
morphology was observed between WT and ΔUS3 BHV-1 infected cells. There was some 
evidence for reorganization of tubulin in WT BHV-1 infected cells but not in ΔUS3 BHV-1 
infected MDBK cells, which may be responsible for this phenotypic change. BHV-1 US3 may 
therefore play an essential role in maintaining adherence between adjacent cells, which could 
affect intercellular spread of the virus. In the absence of US3, the abolishment of the cellular 
projections may explain the difference in growth kinetics between ΔUS3 and WT BHV-1 since 
the virus is unable to spread intercellularly. 
Beyond VP22 being a known substrate for US3, the rationale for investigating its 
subcellular location was that it is involved in cell to cell spread of BHV-1 (54). Since this study 
has demonstrated that ΔUS3 BHV-1 is impaired in cell to cell spread, it was envisioned that 
VP22 may be at least partially responsible for this defect. Furthermore, since VP22 was 
incorporated into the mature BHV-1 virion in higher amounts in ΔUS3 BHV-1 compared to WT 
BHV-1, it was deemed that US3 may have an effect on VP22 expression and possibly  
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Figure 4.9: US3 localizes to the nucleus during BHV-1 infection and is absent in ΔUS3-
infected cells. 
MDBK cells were infected with WT or ΔUS3 BHV-1 at a MOI of 3 for 4 hours in 2-well 
permanox chamber slides before being fixed with paraformaldehyde and permeabilized with 
acetone. Cells were immunostained using US3-specific PAb and Alexa Fluor 633 goat anti-
rabbit IgG, and coverslips were mounted using Prolong Gold Antifade Reagent with Dapi 
(Invitrogen). Images were acquired using normalized settings on the Zeiss LSM410 confocal 
microscope and enhanced under identical parameters using the ImageJ software system.  
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Figure 4.10: BHV-1 US3 may affect maintenance of cellular adhesions that are facilitated 
through cytoskeleton restructuring.  
MDBK cells were infected with WT or ΔUS3 BHV-1 at a MOI of 3 for 4 hours in 2-well 
permanox chamber slides before being fixed with paraformaldehyde and permeabilized with 
acetone. Cells were immunostained using tubulin-specific MAb and Alexa Fluor 488 goat anti-
mouse IgG, and coverslips were mounted using Prolong Gold Antifade Reagent with Dapi 
(Invitrogen). Images were acquired using normalized settings on the Leica DMI6000 confocal 
microscope and enhanced under identical parameters using the ImageJ software system.  
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intracellular trafficking. To investigate VP22, confocal microscopy was carried out as above, 
except cells were probed with rabbit VP22-specific PAb serum. Although differences in cell 
adherence can be seen in Figure 4.11, there is no noticeable difference in VP22 localization 
between cells infected with either WT or ΔUS3 BHV-1. Namely, at 7 hours post infection VP22 
remained cytoplasmic, and was detected in cellular projections in infected cells, irrespective of 
the presence of US3. 
The subcellular localization of VP8 was investigated since our group has previously 
demonstrated that this viral protein is a substrate of BHV-1 US3 (67), and in HSV-1, US3 and 
UL47 reciprocally regulate their subcellular location in infected cells. In the current study, an 
increase in VP8 production in ΔUS3 BHV-1 infected cells and a significant decrease in VP8 
incorporation in the mature ΔUS3 BHV-1 virions was demonstrated. Since VP8 is the major 
tegument protein in BHV-1, decreased incorporation may have an effect on the lifecycle, fitness, 
and/or pathogenicity of the virus in its host. In WT BHV-1 infected cells, VP8 was expected to 
be nuclear but may also have some cytoplasmic staining due to the presence of a nuclear export 
signal (158).  
To investigate the subcellular localization of VP8, slides were prepared as above, except 
cells were fixed and probed with anti-VP8 specific MAb at 7 hours post-infection. Seven hours 
was chosen as our group has previously shown that VP8 translocates to the nucleus after 5 hours 
of infection (144). Figure 4.12 clearly demonstrates that the nuclear localization of BHV-1 VP8 
is not dependent on US3 phosphorylation for its nuclear translocation. These results are in 
contrast to those obtained in HSV-1 infection, and could mean that either BHV-1 VP8 does not 
have to be phosphorylated before nuclear translocation, or could mean that the cellular CK2  
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Figure 4.11: The intracellular localization of BHV-1 VP22 is not dependent on US3. 
MDBK cells were infected with WT or ΔUS3 BHV-1 at a MOI of 3 for 7 hours in 2-well 
permanox chamber slides before being fixed with paraformaldehyde and permeabilized with 
acetone. Cells were immunostained using tubulin-specific MAb and VP22-specific PAb before 
being incubated with Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 622 goat anti-rabbit 
IgG. Coverslips were mounted using Prolong Gold Antifade Reagent with Dapi (Invitrogen). 
Images were acquired using normalized settings on the Leica DMI6000 confocal microscope and 
enhanced under identical parameters using the ImageJ software system. 
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Figure 4.12: BHV-1 VP8 localizes to the nucleus of infected cells independent of US3. 
MDBK cells were infected with WT or ΔUS3 BHV-1 at a MOI of 3 for 7 hours in 2-well 
permanox chamber slides, before being fixed with paraformaldehyde and permeabilized with 
acetone. Cells were immunostained using VP8-specific MAb and US3-specific PAb before being 
incubated with Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 622 goat anti-rabbit IgG. 
Coverslips were mounted using Prolong Gold Antifade Reagent with Dapi (Invitrogen). Images 
were acquired using normalized settings on the Zeiss LSM410 confocal microscope and 
enhanced under identical parameters using the ImageJ software system. 
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kinase, which has been shown to be the primary kinase responsible for BHV-1 VP8 
phosphorylation, may determine its subcellular location (67).  
gB was also investigated by confocal microscopy, since in HSV-1 US3 phosphorylation 
of gB at residue Thr-887 has been shown to regulate its expression on the surface of infected 
cells (55). Since the results presented in our study demonstrate that US3 deletion has a 
significant impact on in vitro gB expression and its incorporation into the mature virion, it was 
envisaged that US3 deletion may also have an effect on gB surface expression in infected cells. 
MDBK cells were infected with WT or ΔUS3 BHV-1 and fixed at 3 and 6 hours post infection to 
investigate the kinetics of gB surface expression. Furthermore, to differentiate between total gB 
cell expression and surface expression of gB, cells were either permeabilized or left 
unpermeabilized during the staining procedure. Fixed cells were stained with a gB-specific MAb 
and a US3-specific PAb. 
The confocal images shown in Figures 4.13 a and b were taken and enhanced under 
identical settings. At 3 hours post-infection, the total expression of gB seemed greater in ΔUS3 
BHV-1 infected cells compared to WT BHV-1 infected cells, which may reflect impaired 
endocytosis of gB from the cell surface early in infection. Once the infection progressed, 
however, it was apparent that the intracellular accumulation of gB is greater in WT BHV-1 
infected cells compared to ΔUS3 BHV-1 infected cells, as is shown at 6 hours post-infection.  
To investigate the surface expression of gB in ΔUS3 BHV-1 infected cells, non-
permeabilized cells which were stained identical to the permeabilized cells were examined using 
confocal microscopy. Figures 4.14 a and b clearly demonstrate that the surface expression of gB 
was higher 3 hours post infection in cells infected with ΔUS3 BHV-1 when compared to WT 
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BHV-1. By 6 hours post infection, however, the difference became difficult to discern which 
may reflect cells adopting a round morphology at this late time point.  
4.8 Effect of US3 on the surface expression of gB in vitro  
 To quantify the differences in gB surface and intracellular expression in MDBK cells 
infected with either ΔUS3 or WT BHV-1, FACS was carried out. As demonstrated in Figure 
4.15, the accumulated intracellular gB was approximately 25% higher in WT BHV-1 infected 
cells than in cells infected with ΔUS3 BHV-1. This decrease in intracellular gB in ΔUS3 BHV-1 
infected cells is associated with a corresponding 25% increase in surface gB expression in cells 
infected with ΔUS3 BHV-1 compared to cells infected with WT BHV-1. Confirmation of these 
results through replicate experiments will allow for statistical analysis. Furthermore, FACS 
analysis comparing WT and US3R BHV-1 infected cells will confirm that the observed effect on 
gB is due to BHV-1 US3 alone.  
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Figure 4.13 a,b:  Intracellular expression of gB in cells infected with WT and ΔUS3 BHV-1. 
MDBK cells were infected with WT or ΔUS3 BHV-1 at a MOI of 3 for 3 (a.) or 6 (b.) hours in 
2-well permanox chamber slides, before being fixed with paraformaldehyde and permeabilized 
with acetone. Cells were immunostained using gB-specific MAb and US3-specific PAb before 
being incubated with Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 633 goat anti-rabbit 
IgG. Coverslips were mounted using Prolong Gold Antifade Reagent with Dapi (Invitrogen). 
Images were acquired using normalized settings on the Leica DMI6000 confocal microscope and 
enhanced under identical parameters using the ImageJ software system. 
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Figure 4.14 a,b: Surface expression of gB in cells infected with WT and ΔUS3 BHV-1. 
MDBK cells were infected with WT or ΔUS3 BHV-1 at a MOI of 3 for 3 (a.) or 6 (b.) hours in 
2-well permanox chamber slides before being fixed with paraformaldehyde. Cells were 
immunostained using gB-specific MAb and US3-specific PAb before being incubated with 
Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 633 goat anti-rabbit IgG. Coverslips were 
mounted using Prolong Gold Antifade Reagent with Dapi (Invitrogen). Images were acquired 
using normalized settings on the Leica DMI6000 confocal microscope and enhanced under 
identical parameters using the ImageJ software system. 
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Figure 4.15 a, b, c: Intracellular and surface expression of gB in WT and ΔUS3 BHV-1. 
MDBK cells were infected at a MOI of 3 and harvested at 4 hours post-infection. Cells were 
either permeabilized according to the procedure in Materials and Methods, or nonpermeabilized. 
Cells were then immunostained with gB-specific MAb and Alexa Fluor 488 goat anti-mouse 
IgG. A) The MFI of cells expressing intracellular gB was determined by FACS analysis. B) The 
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MFI of cells expressing gB on the surface was determined by FACS analysis. C) The relative 
MFI of cells infected with ΔUS3 BHV-1 compared to WT BHV-1 are shown. The bars are 
represented as the means from two independent experiments after the MFI from mock-infected 
MDBK cells was subtracted. Standard deviations are presented.  
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5.0 DISCUSSION AND CONCLUSIONS 
 
 BHV-1 causes a range of clinical manifestations in cattle including respiratory and 
genital infections which range in severity depending on the strain. Of particular economic 
importance is the role that BHV-1 plays in the development of BRDC, a severe respiratory 
disease in cattle which may also lead to milk drop, abortions, and death in infected animals. 
BHV-1-mediated immunosuppression of the host contributes to BRDC by allowing the 
establishment of secondary infections (51). BHV-1 is an enormous economic concern in 
countries harboring large cattle populations, such as those in North America. It has been 
estimated that BRDC or „shipping fever‟ costs the US cattle industry close to one billion dollars 
per year (11, 133).  
 While culling of seropositive herds has been effective in some European countries, 
vaccination remains the most effective means of BHV-1 control in countries which harbor large 
cattle populations. Efforts to develop an inexpensive, safe, and effective vaccine against BHV-1 
have been an ongoing since the early 1980‟s (48). While various vaccines against BHV-1 have 
been successful at reducing disease severity, transmission, and replication of the virus, none have 
been able to prevent infection (1). Commercially available vaccines against BHV-1 include 
MLV and inactivated vaccines, which have issues with safety and efficacy, respectively. 
Although MLV produce rapid and enduring immune responses, safety issues have prevented 
these vaccines from being highly successful (139, 150). Alternatively, KV against BHV-1 have 
outstanding safety profiles, yet fail to elicit appropriate immune responses and often require 
adjuvants. Due to these issues, genetically engineered gene-deleted, subunit, DNA, and vectored 
vaccines are being investigated as alternatives to the commercially available vaccines against 
BHV-1.  
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 To design effective vaccines, more information is required on the contributions of 
individual BHV-1 gene products to the viral lifecycle and pathogenicity in the host. US3 is one 
of two serine/threonine kinases which are expressed by the alphaherpesvirus subfamily (114). 
Although non-essential, US3 has been shown to contribute to viral fitness and pathogenicity in 
related alphaherpesviruses through multifunctional roles in the viral lifecycle, including efficient 
viral gene expression, virion morphogenesis, cytoskeleton reorganization and evasion of the 
antiviral response (22). While the functions of US3 in HSV-1 and PRV infection have been 
studied extensively, the function(s) of US3 during BHV-1 infection remain poorly understood.  
Studies on BHV-1 US3 have elucidated two viral substrates, namely VP8 and VP22 (66, 
67). Both of these viral proteins play vital roles in the BHV-1 lifecycle, including efficient viral 
gene transcription and facilitating intercellular virus spread, respectively. Recently, Brzozowska 
et al. (14) demonstrated that similar to BHV-5, PRV, and HSV-2 (30, 32, 68, 141), BHV-1 US3 
induces cytoskeleton changes that are characteristic of BHV-1 infection. Since this study was 
conducted using a recombinant baculovirus system, more research is needed to identify the roles 
of BHV-1 US3 on cytosketon arrangements within the context of infection and also elucidate a 
reason for this drastic cellular modification. The role of BHV-1 US3 in cell to cell spread was 
recently shown to be strain-dependent, with the US3 protein playing an integral role in 
intercellular spread with a highly passaged strain compared to a minimally passaged strain (90). 
This group also demonstrated that when US3 was deleted, the in vitro growth kinetics of the 
virus were impaired. From these studies, it is clear that while BHV-1 US3 is non-essential, it 
plays vital roles in viral fitness and potentially in the pathogenicity of the virus in its host.  
 The objective of our study was to functionally characterize the BHV-1 US3 kinase in an 
effort to identify roles for US3 in the BHV-1 lifecycle and fitness of BHV-1. To carry out these 
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studies, a ΔUS3 BHV-1 and corresponding US3R BHV-1 were generated. The viruses were 
characterized alongside WT BHV-1. In vitro growth kinetics, viral protein expression kinetics, 
and mature virion composition were all investigated. To further elucidate a role for US3 in the 
BHV-1 lifecycle, the effect that US3 has on cell to cell spread and cellular morphology in the 
context of infection were determined. Finally, the effect US3 has on the intracellular localization 
of known substrates, VP8 and VP22, and a putative substrate, gB, were explored through 
confocal microscopy and flow cytometry (for gB).   
After generating a ΔUS3 BHV-1 and the corresponding US3R BHV-1, the growth 
kinetics of the mutant viruses were investigated. Using a single-step growth assay, we found that 
ΔUS3 BHV-1 had approximately 10-fold lower intracellular and extracellular titres at late stages 
of infection compared to either WT or US3R BHV-1. These results are consistent with the work 
of Minh et al. (90). Additionally, starting at around 15 hours post infection, the titres of ΔUS3 
BHV-1 plateaued and remained consistent throughout the course of infection. This is in contrast 
to the pattern seen with the WT and US3R BHV-1, which had increasing titres throughout the 
entire time course. The overall observed defect in the growth kinetics of ΔUS3 BHV-1 could be 
due to a deficiency in cell to cell spread, egress of the virus from the cell, or could reflect lower 
viral replication rates in the absence of US3. More research is required to identify the mechanism 
of this impairment.  
 The effect that US3 has on the expression kinetics of major structural and regulatory 
proteins was investigated. This analysis was used to identify roles that US3 may play during 
BHV-1 infection and the viral protein cascade. We found that compared to WT, ΔUS3 BHV-1 
infected cells exhibited differences in bICP4 and VP5 protein expression. Specifically, compared 
to WT BHV-1, the immediate-early protein, bICP4, which was expressed earlier in infection and 
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the major capsid protein, VP5, was expressed in higher amounts throughout the duration of 
infection in ΔUS3 BHV-1 infected cells. Since the WT and ΔUS3 BHV-1 stocks were titred in 
quadruplicate in three independent experiments, we can be confident that the increased 
production of these proteins was not due to differences in virion input. 
 Other viral proteins which were most affected by the deletion of US3 included the major 
tegument proteins, VP16 and VP8, which were expressed in higher amounts during late stages of 
infection compared to WT infected cells. Also, cellular gB expression was higher with ΔUS3 
BHV-1 early in infection, with levels that tapered off over the remainder of infection. gC 
expression, on the other hand, was reduced by half compared to WT infected cells throughout the 
course of infection. Viral proteins whose expression seemed unaffected by the deletion of US3 
included gD and VP22, which remained fairly consistent in cells infected with either virus 
throughout the course of infection. These data support a role for US3 in the regulation of major 
structural and regulatory viral protein expression during the course of infection.  
 The differences in the cellular expression of these BHV-1 proteins in the absence of US3 
could be due to a number of mechanisms. The expression of viral proteins such as VP8, VP16, 
and gB, were increased in cells infected with ΔUS3 BHV-1 compared to WT BHV-1. It can be 
speculated that US3 could have a direct effect on the phosphorylation profile of these proteins, 
and when they are hypophosphorylated, may make them more resistant to degradation. Indeed, 
phosphorylation by herpesvirus protein kinases has been shown to target cellular and viral 
proteins for ubiquination and subsequent proteosomal degradation (17, 47). On the contrary, the 
decreased expression of gC in the absence of BHV-1 US3 could point to an interaction of this 
protein with BHV-1 US3 (through phosphorylation or other means), which could potentially 
make gC more stable during normal WT BHV-1 infection. Also, since PRV US3 has been shown 
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to remain with the capsid until it docks at the nuclear pore, potentially BHV-1 US3 has similar 
trafficking, and could affect viral protein expression either directly or indirectly (35). Increased 
intracellular expression of the immediate-early protein, bICP4, suggests that BHV-1 US3 may 
have a regulatory role in viral gene transcription. It is unclear at this time how BHV-1 US3 
affects the expression profiles of various viral proteins; however, it is tempting to believe that 
either direct phosphorylation of these proteins or other regulatory viral or cellular proteins may 
be important for efficient viral protein expression. 
HSV-1 gB phosphorylation by US3 has been demonstrated to have numerous important 
roles in vitro (44), including influencing gB trafficking and cellular localization. Kato et al. have 
demonstrated that in HSV-1, US3 is responsible for the direct phosphorylation of gB in infected 
cells, which regulates its intracellular localization (55). Follow-up studies by Imai et al. have 
further identified four residues in gB which are required for efficient gB trafficking in cells 
infected with HSV-1 (43). This group determined that US3-dependent phosphorylation of gB at a 
position 887 threonine residue is required for efficient downregulation of gB on the surface of 
infected cells. Although this residue is not present in BHV-1, there are numerous other serine 
and threonine residues in the cytoplasmic region of gB which are BHV-1 specific, and may play 
roles in the US3-dependent regulation of gB surface expression in infected cells (151).  
Although gB is not a known substrate for BHV-1 US3, our in vitro expression kinetics 
studies have demonstrated that US3 deletion affects the intracellular expression of gB. Namely, 
in ΔUS3 BHV-1 infected cells, gB levels are increased early in infection and taper off for the 
remainder of infection compared to WT BHV-1. It is tempting to believe that US3 either directly 
or indirectly affects its intracellular expression and/or prevents gB degradation. The mechanism 
for this regulation is likely through phosphorylation of gB by US3, similar to HSV-1 (44). 
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To determine the effect that BHV-1 US3 has on the integration of viral proteins into the 
mature virion, we determined the composition of purified WT, ΔUS3 and US3R BHV-1. We 
found that similar to the effect on viral protein expression kinetics, the incorporation of various 
viral proteins into the mature virions were different in the ΔUS3 BHV-1 compared to WT or the 
US3R virus. Quantitative analysis using densitometry demonstrated that compared to WT, ΔUS3 
BHV-1 has approximately 50% increased incorporation of gB, 50% decreased incorporation of 
VP8 and VP16,  40% increased incorporation of VP22, and 25% increased incorporation of gD. 
gC was the only protein investigated with equal amounts of protein incorporated into the mature 
virion irrespective of US3. Viral protein incorporation into US3R BHV-1 was approximately the 
same as that in WT BHV-1, further demonstrating that this virus had reverted to its WT 
phenotype. These results demonstrate that US3 is required for efficient incorporation of a 
number of viral proteins into the mature BHV-1 virion.  
Similar to what has been demonstrated in a VP8-null BHV-1 (73), the deletion of BHV-1 
US3 has resulted in both increased and decreased amounts of certain key proteins in the mature 
virion. Compared to WT BHV-1, ΔUS3 BHV-1 has increased levels of VP22 and gB, and 
decreased levels of VP16 and VP8. Besides gB, these trends are not reflected in the expression 
kinetics profiles of these proteins in the infected cell. To explain these discrepancies, there are a 
number of possibilities.  
Similar to the effect that VP8 deletion has on gC in BHV-1 (73), the incorporation of 
VP16 and VP8 into the mature virion could be dependent on WT BHV-1 expression levels of 
US3. Since VP8 is a known substrate of BHV-1 US3, it can be envisaged that reduced 
phosphorylation of this protein may reduce its assembly into the mature virion. In contrast with 
this idea, various groups have shown that although alphaherpesvirus VP22 homologues are 
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phosphorylated during infection, the unphosphorylated form of the protein predominates in the 
mature virion (26, 37).  It is not known if US3 phosphorylates VP16 in BHV-1, however, our 
results suggest that this is a possibility. Alternatively, US3 in BHV-1 could play a physical role 
in recruiting VP16 and VP8 into the tegument. Recently, HSV-1 VP22 was shown to play an 
integral role in the recruitment of various glycoproteins into the tegument (80).  
Although VP22 was substantially increased in the virion in the absence of BHV-1 US3, 
the levels of intracellular VP22 were roughly equal to WT levels. Similar to what has been 
demonstrated in a VP8-null BHV-1, the decreased incorporation of the major tegument proteins, 
VP8 and VP16, could drive increased incorporation of VP22 in the absence of BHV-1 US3 (73). 
Alternatively, similar to what has been found in HSV-1 and HSV-2, hypophosphorylation of 
VP22 at serine/threonine residues could increase the capacity to which it is incorporated into the 
tegument (26, 37). More research is obviously needed to identify how BHV-1 US3 physically 
interacts with VP8, VP16, and VP22, and affects their incorporation into the mature virion. This 
is a daunting task, as tegumentation of BHV-1 is a complex process that is driven by an intricate 
cascade of protein-protein interactions.  
The marked increase in gB incorporation into mature virions in the absence of US3 points 
further to a significant role for BHV-1 US3 in the intracellular trafficking and regulation of gB 
expression in vitro. Although HSV-1 gB has been shown to be a substrate for US3, this has not 
been demonstrated in BHV-1 (55). The corresponding decrease in the major tegument proteins, 
VP16 and VP8, also point to a role for US3 in their regulation. To date, VP16 has not been 
identified as a substrate for US3 in BHV-1. Studies in PRV, however, have demonstrated that 
when US3 is deleted, the incorporation of both the large and small isoforms of VP16 are 
minimally increased (87).  
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Our group has previously demonstrated that VP8 is a substrate for US3 (67), however, 
the function that this plays in vitro has not been investigated. To elucidate a potential role for the 
phosphorylation of VP8 by US3, confocal microscopy was carried out on either WT or ΔUS3 
BHV-1 infected cells using antibodies against US3 and VP8. We demonstrated that in both the 
presence and absence of US3, VP8 localizes to the nucleus during infection. This US3-
independent nuclear localization of VP8 was unexpected since a putative phosphorylation 
residue on VP8 is close to one of the four nuclear import signals (67, 145, 158). This means that 
the nuclear translocation of VP8 likely occurs through a US3-independent process involving 
cellular kinases or that this process may not require phosphorylation at all. Furthermore, contrary 
to what has been found by Kato et al. in HSV-1, BHV-1 US3 and VP8 do not seem to 
reciprocally regulate their nuclear localization during infection as VP8 is nuclear independent of  
US3 (56) 
US3 deletion also resulted in increased incorporation of VP22, a tegument protein 
important in BHV-1 cell to cell spread (54). Our group has shown that US3 is involved in 
phosphorylating VP22 in vitro, however, the function of this modification is still unclear (66). To 
determine whether US3 deletion has an effect on cell to cell spread of the virus, the relative 
plaque sizes of the WT, ΔUS3, and US3R BHV-1 were determined. We found that relative to 
WT or US3R BHV-1, the US3-deleted virus was significantly impaired (p≤0.0001) in cell to cell 
spread. There was no difference, however, in the cellular localization of VP22 in the presence or 
absence of US3, with the protein being entirely cytoplasmic at 7 hours post-infection 
independent of US3. Similarly, phosphorylation of VP22 in HSV-2 has been shown to not be 
required for its subcellular localization (36). Taken together, our results show that US3-
dependent phosphorylation of VP22 is not required for its cytoplasmic localization at early times 
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post-infection. This localization may be independent of phosphorylation or could be dependent 
on the cellular casein kinase 2 (CK2), which has been demonstrated to be the major protein 
which phosphorylates BHV-1 VP22 in vitro. It is still possible, however, that the 
hypophosphorylation of VP22 in the absence of US3 in ΔUS3 BHV-1 may be responsible for the 
defect in cell to cell spread of  this virus.  
Consistent with the results from Brzozowska et al., our studies show that US3 causes 
substantial changes in the host cell morphology during infection (14). Although difficult to 
discern from our studies, Brzozowska et al. have shown outside of the context of infection that 
the phenotypic changes are due to US3-dependent actin reorganization, resulting in microtubule 
formation. In PRV, similar US3-dependent cytoskeleton reorganizations have been shown to be 
required for efficient intercellular spread of the virus (31). It is tempting to believe that BHV-1 
may use a similar intercellular spread mechanism via tubulin. Our studies demonstrated that cells 
infected with either WT or US3R BHV-1 gradually formed a network of cells which remained 
connected through long cellular extensions, whereas the extensions were absent during infection 
with ΔUS3 BHV-1. Using our ΔUS3 BHV-1 mutant, we were able to demonstrate that this 
phenotype is dependent on US3 and is not compensated for by other viral proteins. Furthermore, 
cells infected with either WT or ΔUS3 BHV-1 began to show distinct phenotypes as early as 15 
hours post infection. Our data also provide some evidence that the US3-dependent cellular 
changes could be due to tubulin reorganization that results in long cellular extensions produced 
during WT BHV-1 infection.  
 In HSV-1, phosphorylation of gB by US3 has been shown to be important for viral egress 
from the outer nuclear membrane (153). During normal HSV-1 infection, gB and gH cooperate 
to promote fusion between the viral envelope and the outer nuclear membrane. Wisner et al. 
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were able to demonstrate that when gB was deleted, HSV-1 virions accumulate in the perinuclear 
space in large herniations. A similar phenotype is seen when US3 is deleted in HSV-1 or PRV 
(112, 148). Through mutagenesis studies, Wisner et al. showed that phosphorylation of gB at 
Thr-887 in the cytoplasmic tail is responsible for mediating fusion between the outer nuclear 
membrane and the HSV-1 virion. This group suggested that US3 may be packaged in the 
tegument layer in the perinuclear space, which brings it into close vicinity with the Thr-887 
residue on gB, triggering phosphorylation to allow viral egress from the nucleus. Our studies 
have demonstrated that intracellular expression kinetics and incorporation of gB into mature 
virions is increased, and that cell to cell spread is impaired in cells infected with ΔUS3 BHV-1. 
Hypophosphorylation of gB at the cytoplasmic tail may be responsible for this defect in cell to 
cell spread if the virus is impaired in nuclear egress similar to HSV-1.  
 In this project, a role for US3 regulation of gB expression was clearly demonstrated both 
in infected cells and incorporation of the protein into mature virions. Recent studies in HSV-1 
have shown that the phosphorylation of gB by US3 regulates its subcellular localization (44, 55, 
153). Kato et al. have demonstrated through in vitro kinase assays that US3-dependent 
phosphorylation of gB at threonine residue 887 (Thr-887) is required for efficient 
downregulation of gB from the surface of infected cells (55). When US3 was rendered kinase-
dead or when the Thr-887 residue in gB was mutated, it resulted in a significant increase in gB 
surface expression in infected cells which corresponded to a downregulation of endocytosed gB 
from the surface of infected cells (43). Since gB is highly immunogenic, the increased surface 
expression results in reduced pathogenicity in a mouse model (44). Since the results presented in 
this study demonstrate that US3-deletion has a significant impact on gB expression and virion 
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incorporation, we envisaged that US3 deletion may also have an effect on gB surface expression 
in infected cells.  
Therefore, the effect of US3 on gB expression in vitro was investigated. Our results show 
that similar to HSV-1, US3 deletion in BHV-1 results in an increase in gB surface expression, 
especially at early times post infection (i.e. 3 hours post infection) and a decrease in the 
intracellular accumulation of gB at late stages of infection (i.e. 6 hours post infection). The 
difference in surface expression was difficult to ascertain at 6 hours post infection, which may 
reflect cells rounding up at this later time point. These results were demonstrated through 
confocal microscopy, and flow cytometry was used to quantify the expression. Using both 
permeabilized and non-permeabilized cells, the expression levels of intracellular and surface gB 
were assessed. Intracellular gB expression was approximately 25% higher in the WT BHV-1 
infected cells than in cells infected with ΔUS3 BHV-1. This decrease in intracellular gB 
expression in ΔUS3 BHV-1 infected cells was associated with a corresponding 25% increase in 
surface gB expression. This inverse relationship is in agreement with what has previously been 
demonstrated in HSV-1 (43).   
These studies in BHV-1 are to our knowledge, the first to demonstrate that US3 (either 
through direct phosphorylation or by other means) regulates gB expression, incorporation of gB 
into the mature BHV-1 virion, and intracellular trafficking. More specifically, US3 in BHV-1 
was required for efficient endocytosis of gB from the surface of cells, and US3-deletion resulted 
in an upregulation of gB surface expression and a downregulation of accumulated intracellular 
gB. Our studies have demonstrated that gB is packaged into ΔUS3 BHV-1 mature virions at 
levels that are approximately 50% higher than in WT BHV-1, which may reflect more efficient 
packaging when gB is hypophosphorylated in the absence of US3. Furthermore, the decreased 
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growth titres and impairment in cell to cell spread of ΔUS3 BHV-1 compared to WT could be 
due to hypophosphorylation of gB in BHV-1 infected cells, since US3-dependent 
phosphorylation of gB has been shown to be important in nuclear egress in HSV-1 infected cells 
(153). Functional analysis by Miethke et al. has demonstrated that BHV-1 gB is responsible for 
efficient cell to cell spread of the virus, although it has not been elucidated whether US3-
dependent phosphorylation is required for this process (88).  
Based on our studies, we conclude that BHV-1 US3 plays a key role in the lifecycle and 
fitness of the virus in vitro. We have demonstrated that BHV-1 US3 influences the viral growth 
kinetics, the expression kinetics of major structural and regulatory proteins, the incorporation of 
key viral proteins into the mature virion, host-cell morphological changes, and cell to cell spread. 
The effect that US3-deletion has on viral growth kinetics may reflect a deficiency in cell to cell 
spread, egress of the virus from the nucleus, or potentially lower replication rates. US3 may 
influence viral gene expression directly through transcription regulation, or may play a more 
indirect role through modifying (via phosphorylation or other means) other proteins which 
interact directly. BHV-1 US3-deletion has a major effect on the intracellular expression and 
incorporation of two known substrates, VP22 and VP8, into the mature virion. Furthermore the 
expression and incorporation of VP16 and gB into the mature virion were significantly affected 
by US3-deletion, which could mean that these proteins are also substrates of BHV-1 US3. Our 
results also demonstrate that BHV-1 US3 could play a role in the tegumentation process. 
These studies have also demonstrated that the cellular localization of VP22 and the 
nuclear translocation of VP8 at early times post-infection are not dependent on BHV-1 US3. We 
reasoned that although these proteins are known substrates of US3, US3-dependent 
phosphorylation is not required for their cellular localization. The localization of BHV-1 VP8 
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and VP22 may instead be dependent on phosphorylation by other viral and/or cellular proteins, 
or their localization may be independent of phosphorylation all together. On the other hand, 
expression and trafficking of gB was affected by the absence of US3, and in cells infected with 
ΔUS3 BHV-1, the surface expression of gB was increased by approximately 25%. Since gB is 
plays a major role in viral attachment, this could have a large effect on pathogenicity of the virus 
in vivo.  
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6.0 GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
Our study has demonstrated a role for US3 in various aspects of the viral lifecycle and 
has identified potential roles that the protein may play in the fitness of BHV-1.  Specifically, 
US3 has been demonstrated to have an effect on the expression kinetics of a number of major 
regulatory and structural viral proteins, including bICP4, VP5, gB, VP16, VP8, and gC. Normal 
incorporation of these proteins, and others, into the mature virion were also shown to be 
dependent on US3. Of the proteins investigated, the incorporation of the major tegument proteins 
VP8, VP16, and one of the major glycoproteins, gB, into the mature virion were shown to be 
most heavily dependent on the presence of US3. In the absence of US3, incorporation of VP8 
and VP16 into the mature virion was reduced by 50% and incorporation of gB was increased by 
50%. These data likely reflect a significant role for BHV-1 US3 in the expression and trafficking 
of viral proteins. More research is needed to identify the mechanism(s) by which US3 affects the 
intracellular expression and incorporation of these major proteins into the mature virion. As most 
of the proteins investigated are not known substrates of BHV-1 US3, it would also be useful to 
identify which of these viral proteins are phosphorylated by US3.  
The effect that US3 has on BHV-1 growth kinetics and cell to cell spread of the virus was 
investigated. Using a single-step growth assay, we demonstrated that in the absence of US3, 
BHV-1 growth was impaired by approximately 10-fold. Furthermore, titres plateaued at 15 hours 
post infection compared to WT infected cells. We envisaged that viral growth impairment in the 
absence of US3 could reflect a deficiency in cell to cell spread of the virus, egress of the virus 
from the cell, or lower replication rates. Through a plaque size analysis, we were also able to 
identify that US3 plays a major role in cell to cell spread of BHV-1. We demonstrated that cells 
infected with US3-deleted BHV-1 formed significantly smaller plaques that cells infected with 
90 
 
WT BHV-1. It is clear that more research is required to identify the role(s) that US3 plays in 
BHV-1 in vitro growth kinetics and cell to cell spread. 
Although it is unclear how BHV-1 US3 affects cell to cell spread in the virus, we 
envisaged that it could be through phosphorylation of VP22 and/or a putative substrate, gB. 
Studies in HSV-1 have shown that US3-dependent phosphorylation of gB at its cytoplasmic tail 
is required for efficient egress of the virus from the cell (153). VP22 has been identified as a 
substrate for US3 in BHV-1 and its role in cell to cell spread has been well documented (54, 66). 
Although we determined that BHV-1 is impaired in intercellular spread in the absence of US3, 
we could not find any difference in the cellular localization of VP22 in either the presence or 
absence of US3. We envisaged that the subcellular localization of VP22 could be independent of 
phosphorylation or could be dependent on CK2 phosphorylation.  Follow-up studies could 
include identifying the residue(s) in gB which are phosphorylated by US3 and carrying out a 
functional mutagenesis study to determine whether US3-dependent phosphorylation of these 
residues affects the intercellular spread of BHV-1. Also, examining VP22 localization at late 
times post-infection in the absence of US3 may determine whether US3-dependent 
phosphorylation is required for nuclear translocation, as has been investigated by Labiuk et al. 
(62).  
Although VP8 was previously identified as a substrate of US3 in BHV-1, our microscopy 
studies have demonstrated that the nuclear localization of VP8 is not dependent on 
phosphorylation by US3 (67). This observation was unexpected, since a putative phosphorylation 
residue on VP8 is in close proximity to one of the four nuclear import signals (67, 145, 158). 
This may mean that the nuclear translocation of VP8 occurs through a process that is 
independent of US3 phosphorylation involving cellular kinases, or that phosphorylation is not 
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required for the translocation. A systematic mutagenesis study is required to determine which (if 
any) of the VP8 nuclear import signals require phosphorylation for efficient translocation of the 
protein into the nucleus. 
Our study is, to our knowledge, the first to demonstrate in the context of infection that 
BHV-1 US3 is required for cellular morphological changes that are characteristic of WT BHV-1 
infection. Our microscopy studies have demonstrated a markedly different phenotype in cells 
infected with WT BHV-1 compared to a US3-deleted BHV-1. The altered phenotype could be 
rescued in the presence of US3. These cellular morphological differences could be due to tubulin 
reorganization. Since US3-dependent cytoskeleton changes have been shown to be required for 
efficient spread of PRV (31), it is tempting to believe that BHV-1 may use a similar mechanism. 
This could also explain why BHV-1 growth titres and plaque sizes were significantly impaired in 
the absence of US3. Future directions should involve further studies on cytoskeleton 
reorganization by US3 during BHV-1 infection, and if confirmed, identifying whether this might 
be required for efficient cell to cell spread of the virus by comparing intercellular spread of GFP-
labeled viruses, similar to studies by Favoreel et al. (28).   
Finally, this study provides preliminary evidence that BHV-1 US3 regulates the 
intracellular trafficking of gB, similar to HSV-1 (43, 44). Using microscopy and flow cytometry 
in the absence of BHV-1 US3, gB tended to be upregulated at the cell surface by approximately 
25%, especially at early times post infection, and the intracellular accumulation of gB was 
reduced by approximately 25% compared to cells infected with WT BHV-1. Confirmation of 
these data, as well as inclusion of the US3R BHV-1 virus is required. Similar to Imai et al., a 
systematic mutational analysis is required to determine which residues in gB which are required 
for US3-dependent downregulation of gB surface expression (43). 
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In closing, this study has demonstrated that BHV-1 US3 plays important roles in the viral 
lifecycle, including in vitro growth, expression kinetics of major BHV-1 proteins, intercellular 
spread of the virus, and integration of major structural viral proteins into the mature virion. 
Additionally, we have provided evidence that BHV-1 US3 influences cellular morphology 
during infection, and affects the intracellular localization of a known substrate, VP8, and a 
putative substrate, gB. Finally, we have demonstrated a novel role for US3 in the intracellular 
trafficking of gB in BHV-1 infected cells. In the future, determining other viral substrates of 
BHV-1 US3, including important residues, will shed light on the mechanisms behind how US3 
affects the viral lifecycle and fitness of BHV-1. After thorough characterization of BHV-1 US3 
in vitro, the next step will be determining which roles US3 plays in vivo to determine its 
suitability in BHV-1 vaccine development. 
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